ISO 14971 - The Standards Navigator

ISO 10993 Contact Duration Matrix- How to Select Tests (2026 Guide)

ISO 10993-1:2025 retired the old Table A.1 checklist approach to biocompatibility testing. This guide explains the current contact duration categories, how total exposure period is calculated for reusable devices, and which biological endpoints apply — including FDA’s partial recognition of the new edition.

ISO 10993 Contact Duration Matrix and Biological Endpoint Selection Explained

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

The Matrix Changed. If Your Biological Evaluation Plan Still Reads Like 2018, You Have a Gap

Table A.1 is gone. For seven years, biological evaluation plans were built around a single grid in Annex A of ISO 10993-1:2018 — cross-reference device category and contact duration, check the boxes, done. That table has been retired. ISO 10993-1:2025, published November 18, 2025, split it into four separate tables and rebuilt the exposure-duration logic underneath them.

ISO 10993-1:2025 is the international standard that guides biocompatibility and biological evaluation of medical devices using a risk-based framework, replacing the prescriptive checklist approach of the 2018 edition.

If your BEP still cites the 2018 ISO 10993 contact duration matrix, or if you categorized a reusable device’s contact duration based on a single use rather than total exposure period, you may already be carrying a documentation gap — one that surfaces exactly when a reviewer or notified body opens your file.

Regulatory affairs teams are asking a narrower question than “what is ISO 10993”: which biological endpoints does this specific device trigger under the current framework, and why. That’s what this guide walks through.

I’ve sat across the table from an auditor reviewing a biological evaluation plan where the contact duration category didn’t match the device’s actual use pattern — a reusable component that looked like “limited” contact on paper but was accumulating well past 24 hours across a single patient’s treatment course. The documentation existed. The categorization logic behind it didn’t hold up. That’s the gap this guide is built to close before it becomes a finding.

👉 Before you finalize your next biological evaluation plan, run it against a structured QMS gap check first. Get the free ISO 13485 Gap Assessment Checklist and confirm your documentation controls support the categorization decisions your BEP depends on.

In This Guide

What changed in the ISO 10993-1:2025 evaluation matrix and why Table A.1 was retired
The current contact duration categories and how “total exposure period” is calculated
How to categorize daily contact, intermittent contact, and reusable devices correctly
Which biological endpoints apply to each contact duration and body-contact combination
What FDA’s partial recognition of ISO 10993-1:2025 means for your submission
Common categorization mistakes that trigger additional testing requirements
Where to buy the current standard and where to get ISO 13485-aligned training

👉 Start Here (Top Resources)

ISO 10993-1:2025 — ANSI Webstore — the current edition, direct from the accredited source. Use code CC2026 for 5% off. (Eric: insert the exact ANSI product link for ISO 10993-1:2025 here.)
If you’re weighing whether to buy standards individually or as a set, the ANSI bundle option is worth checking before you purchase the 10993 series piece by piece.
ISO 13485 Training — BSI Group — for teams building biological evaluation competency into a certified QMS.
ISO Training Courses — ISOQAR — a second accredited training option worth comparing against BSI on schedule and price.

Why the Evaluation Matrix Was Restructured

Under ISO 10993-1:2018, Annex A Table A.1 organized devices by body contact category — surface, external communicating, implant — crossed with three contact duration bands, and listed an “X” for every biological endpoint a reviewer might expect to see addressed. Industry insiders came to call it the “Table A.1 mentality”: manufacturers treated the X’s as a mandatory checklist rather than a starting point for risk-based justification. Tests got run because they appeared in a cell, not because a documented risk assessment called for them.

ISO 10993-1:2025 splits that single table into four separate tables, each tied to a specific evaluation context, and embeds the framework more tightly into the ISO 14971 risk management process. The standard now expects a Biological Evaluation Plan built on the device’s actual risk profile — chemical characterization, materials history, intended use, contact pattern — with the tables used to check completeness, not generate a test order.

Most common finding: biological evaluation plans that cite “Table A.1” by name, or that list endpoints without a documented rationale tied to the device’s specific exposure profile. Under the current standard, that’s a gap a reviewer will flag.

If you are still building your first BEP for a device entering the medical device space, start with what the supplier controls requirements under ISO 13485 expect from your materials documentation — biological evaluation depends heavily on having reliable supplier and materials data before you ever get to a test matrix.

Contact Duration Categories, Defined

The three contact duration categories are unchanged in name but recalculated in practice:

Category	Cumulative Contact	Typical Devices
Limited	Up to 24 hours total	Diagnostic swabs, single-use syringes, short procedural instruments
Prolonged	More than 24 hours, up to 30 days total	Wound dressings changed over several weeks, indwelling catheters (short-term), orthodontic devices
Long-term / Permanent	More than 30 days total	Implants, permanent orthopedic hardware, long-term catheters

The category itself hasn’t moved. What changed is how you calculate “total contact” for a device that isn’t used in one continuous stretch — and that recalculation is where most categorization errors happen.

If you are evaluating a device used in short, repeated sessions → don’t categorize based on a single session length. The standard expects you to sum all contact time across the device’s full use pattern before assigning a category.

Daily Contact vs. Intermittent Contact

Comparison infographic explaining daily contact and intermittent contact under ISO 10993-1:2025 for biological evaluation of medical devices. — ISO 10993-1:2025 distinguishes between daily and intermittent contact when determining cumulative exposure for biological evaluation.

ISO 10993-1:2025 formalizes two exposure patterns that the 2018 edition handled inconsistently:

Daily contact — the device touches the body every day, for any portion of a day, across a defined treatment course. Total exposure is counted as calendar days from first use to last use (or replacement) on a single patient.
Intermittent contact — use with at least 24 hours between consecutive contacts. This is treated as repeated use of the same device, or a replacement device, under evaluation.

A wound contact layer changed daily over three weeks is the textbook example: under the 2018 edition, each dressing change might have been assessed as its own “limited” exposure. Under the current standard, the 21 cumulative contact days push the device into prolonged territory — and that shift can add endpoints your original evaluation never considered.

If you are re-evaluating a device that was cleared under the 2018 categorization logic → don’t assume your existing category still holds. Run the total exposure period calculation against the current definitions before you finalize anything for a new submission.

Reusable Devices and Total Exposure Period

Reusable devices are now categorized based on cumulative contact time for a single patient across the device’s full use pattern — not the duration of any one use, and not a multi-patient device service-life total. A reusable surgical instrument sterilized and reused across a procedure series looks brief per individual contact, but the relevant figure is how many total contact days that one patient accumulates across their treatment course, including reasonably foreseeable misuse such as use beyond the labeled reprocessing cycle count.

Bioaccumulation is a related but less settled consideration. FDA’s Supplementary Information Sheet for ISO 10993-1:2025 (Recognition No. 2-313) notes that ISO/TC 194 Working Group 1 is still developing technical reports specifically addressing bioaccumulation, intermittent contact, and reasonably foreseeable misuse. In practice: if chemical characterization data — extractables and leachables — raises a bioaccumulation concern, that finding should inform your risk assessment and may support escalating the device’s category, but document it as a risk-based judgment rather than treating it as a fixed clause requirement until the supporting technical reports are finalized.

For teams managing this inside a certified QMS, it’s a judgment call that needs to trace back to a documented decision — not a verbal risk call made in a meeting. Clause 9 of ISO 10993-1:2025 requires that biological evaluations be planned, conducted, and reported by competent personnel, with the evaluation report documenting the rationale behind risk decisions like this one. The CAPA requirements under ISO 13485 apply just as much to a categorization correction as to a nonconformance on the shop floor.

Flowchart explaining cumulative single-patient exposure for reusable medical devices under ISO 10993-1:2025. — Reusable medical devices are categorized using cumulative single-patient exposure rather than the duration of a single procedure.

Mapping Contact Category to Biological Endpoints

The biological effects under consideration haven’t fundamentally changed — cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects, and hemocompatibility remain the backbone, and ISO 10993-1 remains a risk-based framework, not a mandatory testing checklist. What changed is the scope of consideration required, particularly for genotoxicity:

Contact Duration	Body Contact	Genotoxicity Consideration
Limited	Any	Case-by-case, per risk assessment
Prolonged	All tissues except intact skin	Generally expected to be addressed per Tables 2–4 and Clause 6.5.7
Long-term / Permanent	All tissues except intact skin	Generally expected to be addressed per Tables 2–4 and Clause 6.5.7

Under the 2018 edition, genotoxicity was consistently expected for implants and long-term tissue contact, but inconsistently applied to prolonged-contact devices touching mucosal membranes or breached surfaces. ISO 10993-1:2025 narrows that inconsistency: per Tables 2–4 and Clause 6.5.7, any device requiring systemic toxicity evaluation due to prolonged or long-term contact is now generally expected to address genotoxicity as well, intact skin excepted — though this remains a risk assessment expectation to be justified within your Biological Evaluation Plan, not an automatic in vivo test order. Where existing data (toxicological risk assessment under ISO 10993-17, chemical characterization, or literature) already addresses the risk adequately, testing may not be necessary. Carcinogenicity consideration was similarly extended for long-term contact with intact mucosal membranes.

Worth flagging directly: FDA’s Supplementary Information Sheet for ISO 10993-1:2025 (Recognition No. 2-313) identifies a genuine discrepancy here. ISO 10993-1:2025 lists genotoxicity as an endpoint for consideration across all prolonged-contact device categories, while FDA’s own Table A.1 (Attachment A of its 2023 Biocompatibility Guidance) limits the genotoxicity endpoint to implanted devices, externally communicating devices with tissue/bone/dentin contact, and externally communicating devices with circulating blood contact. For a U.S. submission, don’t assume the broader ISO scope automatically controls — confirm which framework your reviewer expects you to follow.

Most common finding: biological evaluation plans for prolonged-contact mucosal devices that address systemic toxicity but don’t document a genotoxicity rationale one way or the other — an omission that was easier to overlook under the 2018 matrix and is more likely to draw a question under the current one.

If your device’s evaluation also touches sterilization residuals, review our sterilization standards overview — ethylene oxide and other sterilization residues are a recurring driver of chemical characterization findings that reshape a biological evaluation.

FDA’s Partial Recognition — What’s Excluded

FDA recognized ISO 10993-1:2025 on May 25, 2026 (Recognition No. 2-313 in FDA’s Recognized Consensus Standards database), but the recognition is partial, not full. Two carve-outs from the Supplementary Information Sheet matter for submission strategy:

The phrase “consumer products or” in Clause 6.5.11.3 (Low Risk Intact Skin Contacting Medical Devices) is not recognized — FDA states it conflicts with Attachment G of its 2023 biocompatibility guidance, which limits which historical-use materials qualify for reduced testing on skin-contacting devices.
Clause 6.9, Biological risk estimation, is not recognized — FDA holds it conflicts with the risk estimation approach already established under ISO 14971:2019, which FDA separately recognizes.

If you are preparing a 510(k), PMA, or De Novo submission → you cannot submit a full Declaration of Conformity without addressing these two exclusions directly, and the genotoxicity discrepancy above is a separate, related point worth raising with your reviewer proactively. Cite the standard, but demonstrate compliance for the excluded clauses through FDA’s existing biocompatibility guidance rather than assuming automatic alignment. FDA’s recognized standard entry and Supplementary Information Sheet have already been updated since publication — verify the current version directly against FDA’s Recognized Consensus Standards database before finalizing any submission.

For the broader shift this represents in medical device documentation expectations, see our breakdown of validation and verification requirements under ISO 13485 and the FDA QMSR.

Common Categorization Mistakes

Infographic highlighting common ISO 10993 biological evaluation and contact duration categorization mistakes for medical device manufacturers. — Many ISO 10993 audit findings result from incorrect categorization logic or incomplete biological evaluation documentation rather than testing failures.

⚠️ Categorizing by single-use duration instead of cumulative single-patient exposure. The single most common error on reusable and repeat-use devices — it understates the contact category more often than it overstates it.

⚠️ Citing “Table A.1” in a current BEP. A reference to the old table structure is a documentation red flag on its own, independent of whether the underlying science holds up.

⚠️ Assuming genotoxicity doesn’t need to be addressed for prolonged mucosal contact. Teams working from older templates default to a 2018-era endpoint list and skip documenting a rationale either way — under the current tables, that gap is more likely to draw a question.

⚠️ Assuming FDA recognition is full, or that ISO and FDA genotoxicity scope match. Building a submission strategy around blanket alignment, without addressing the excluded clauses and the genotoxicity scope discrepancy, invites an avoidable deficiency letter.

If you are unsure whether existing biological evaluation plans need revisiting → they don’t automatically require retesting, but ISO 10993-1:2025 does expect a documented review confirming prior categorization and endpoint rationale still hold under current definitions.

Quick Audit Checklist

✅ Contact duration category calculated from cumulative single-patient exposure, not single-use duration
✅ Reusable/repeat-use devices assessed for total contact days for one patient across their treatment course
✅ Genotoxicity rationale documented for prolonged/long-term contact except intact skin, per Tables 2–4 and Clause 6.5.7
✅ Biological Evaluation Plan references current ISO 10993-1:2025 structure, not legacy Table A.1
✅ FDA submission strategy accounts for the two partially-recognized clauses and the genotoxicity scope discrepancy
✅ Bioaccumulation signals from chemical characterization data reviewed and documented as a risk judgment, not assumed to require automatic escalation ✅ Existing (pre-2025) biological evaluations documented as reviewed against current definitions

FAQ

Does ISO 10993-1:2025 require me to retest devices already on the market?

No. The standard doesn’t mandate automatic retesting for devices with an acceptable safety history. It does expect a documented review confirming prior categorization and evaluation still hold, and an update if a Clause 10 production change triggers a re-review.

Is ISO 10993-1:2018 still valid to use?

FDA’s recognized standards database is the authority for U.S. submissions — verify current recognition status before relying on either edition. For new evaluation plans, aligning with the 2025 edition is the safer long-term position.

What’s the difference between “prolonged” and “long-term” contact?

Prolonged contact covers cumulative contact exceeding 24 hours but not exceeding 30 days. Long-term (permanent) contact covers cumulative contact exceeding 30 days, driven by total exposure period rather than packaging or labeling.

Does the 2025 edition apply to devices regulated under the EU MDR?

It’s generally treated as state of the art for MDR purposes, but grace periods and notified body expectations vary — confirm directly with your notified body.

Is genotoxicity testing now mandatory for every prolonged-contact device?

Not automatically. Per Tables 2–4 and Clause 6.5.7, genotoxicity is generally expected to be addressed through risk assessment for prolonged and long-term contact with all tissues except intact skin — but “addressed” can mean justified through existing toxicological or chemical characterization data, not necessarily new in vivo testing. Note also that FDA’s own Table A.1 applies genotoxicity more narrowly than ISO does, so confirm which framework governs your specific submission.

Do I need a new Biological Evaluation Plan for every device?

No blanket requirement to start over. Most manufacturers can update an existing BEP to reflect current categorization logic and endpoint scope, provided the underlying risk assessment and chemical characterization data are still valid.

How does ISO 14971 relate to my biological evaluation?

ISO 10993-1:2025 is now more tightly embedded in the ISO 14971 risk management process. See our guide on risk management in medical devices under ISO 14971 for how that framework applies.

Where do I buy the current edition of ISO 10993-1?

Through an authorized reseller such as the ANSI Webstore, which also serves international buyers and offers standards in multiple languages. ISO 10993-1:2025 — ANSI Webstore — Coupon code CC2026 applies through December 31, 2026.

📥 Free Resources

ISO 9001 Roadmap — step-by-step implementation guide for manufacturers building or improving a quality management system
Manufacturing Compliance Checklist — practical compliance reference covering key ISO, OSHA, and quality requirements for production environments
Supplier Quality Checklist — evaluation tool for assessing supplier quality controls and flow-down compliance before audits or new contracts
ISO 13485 Gap Assessment Checklist — free checklist for medical device manufacturers assessing their QMS against ISO 13485 requirements

Not Sure What to Do Next?

🔹 Still researching how the current standard applies to your device? Read our Biocompatibility Standards Overview for the full picture before you build a test matrix.

🔹 Ready to build or update your Biological Evaluation Plan? Download the ISO 13485 Gap Assessment Checklist and confirm your documentation controls support the categorization decisions you’re about to make.

🔹 Need to purchase the current standard? ISO 10993-1:2025 — ANSI Webstore — code CC2026 takes 5% off, and international buyers can access the standard in multiple languages through the same source.

The Standard Changed. Your Categorization Logic Should Too.

Table A.1 was a shortcut, and shortcuts age out. ISO 10993-1:2025 asks for a defensible, risk-based answer instead of a checked box — and that’s a better position to defend in front of a reviewer regardless of which edition your notified body is citing this quarter. The Standards Navigator will keep tracking how FDA recognition and international adoption evolve as this transition plays out.

Don’t Let a Reviewer Find the Gap First

Most biological evaluation gaps don’t get caught in your own review — they get caught by a notified body auditor or an FDA reviewer, months after the plan was finalized. Manufacturers who treat contact duration categorization as a one-time exercise tend to carry that risk forward through every product change. Manufacturers who build a documented, repeatable categorization process into their QMS catch the drift before it becomes a submission delay.

The Standards Navigator tracks ISO 10993, ISO 13485, and the broader medical device compliance landscape as it evolves — including regulatory recognition changes like FDA’s partial recognition of ISO 10993-1:2025.

👉 Get updates on medical device biocompatibility and QMS requirements
👉 Be first to access new gap assessment tools and implementation resources

Subscribe below to stay ahead.

The Standards Navigator — Industrial Compliance. Clearly Explained.

Biocompatibility Standards Explained: ISO 10993 Requirements for Medical Devices in 2026

This guide breaks down the ISO 10993 series and the sixth edition of ISO 10993-1, published in November 2025. It covers FDA’s partial recognition of the new edition in May 2026, the two clauses the agency excluded, and whether manufacturers need to revisit biological evaluation plans for devices already cleared.

What ISO 10993-1:2025 and FDA’s Partial Recognition Mean for Your Biological Evaluation Plan

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

The Standard Behind Your Biocompatibility Testing Just Changed — Is Your Documentation Still Defensible?

Biocompatibility standards for medical devices just changed in a way regulatory affairs teams can’t ignore. If your device has any contact with the human body, your biological evaluation plan rests on one standard: ISO 10993-1. For years, that meant the 2018 edition. That’s no longer the whole story.

ISO published a sixth edition, ISO 10993-1:2025, in November 2025. The FDA followed with recognition of that edition on May 25, 2026 — but only partial recognition. Two specific clauses were excluded outright. If your technical documentation, supplier certificates, or biological evaluation reports still cite the 2018 edition without addressing what changed, that’s a gap a reviewer or auditor will find.

This isn’t a cosmetic update. The reorganization ties biocompatibility more tightly to ISO 14971 risk management, and the FDA’s exclusions tell you exactly where the agency still wants you to lean on its own biocompatibility guidance instead of the standard’s language. This guide covers the current medical device biocompatibility testing requirements under both editions, what changed, and what FDA’s recognition decision actually means for your Biological Evaluation Plan (BEP).

I’ve been on the reviewing side of this problem before, just from the documentation control angle. As an ISO 9001 internal auditor, I’ve flagged design history files where a supplier’s certificate of conformance still referenced an outdated edition of a cited standard — the technical content hadn’t changed, but the paper trail no longer matched what the standard actually required. That’s the kind of finding that stalls a submission or an audit closeout, and it’s entirely avoidable if someone catches the edition mismatch before a reviewer does.

Before you touch a single test report, run a gap check on where your current documentation stands against the 2025 edition.

👉 Most teams don’t fail because their biocompatibility data is wrong — they fail because their documentation still points to the wrong edition of the standard. Run the ISO 13485 Gap Assessment Checklist before your next submission or audit →

In This Guide

What ISO 10993-1 covers and why it sits at the center of biocompatibility evaluation
The full ISO 10993 series, part by part
What actually changed in the 2025 edition
FDA’s partial recognition — and exactly what it excluded
Whether you need to retest devices already cleared under the 2018 edition
How biocompatibility documentation fits into your ISO 13485 QMS
A quick audit checklist for your next document review

👉 Start Here (Top Resources)

ISO 10993-1:2025 — ANSI Webstore — the current edition of the core biocompatibility standard, available as an individual purchase or bundled with related parts of the series.
ISO 10993 – Biological Evaluation of Medical Devices Package (bundled, ~45% off individual pricing) — the most cost-effective way to get ISO 10993-1, -5, -6, -7, and related parts together if you’re building out a complete biological evaluation file.
BSI Group ISO 13485 Training — for teams that need to train reviewers or auditors on how biocompatibility evidence fits into the broader QMS, not just the lab side.

What Is Biocompatibility, and Why ISO 10993 Matters

Biocompatibility is the assessment of whether a device’s materials — and the way those materials contact the body — create an unacceptable biological risk. ISO 10993-1 is the standard that governs how you plan, justify, and document that biocompatibility risk assessment. It doesn’t hand you a checklist of tests to run blindly; it requires you to build a risk-based Biological Evaluation Plan (BEP) that considers the device’s materials, manufacturing processes, intended anatomical contact, and exposure duration.

That risk-based framing matters because it’s the same language FDA reviewers and notified bodies expect to see. A BEP that reads like a 2009-era test list, rather than a risk justification tied to ISO 14971, is a common source of review questions and additional information requests.

If you’re still building out your risk management process, our guide on risk management in medical devices under ISO 14971 covers the foundation ISO 10993-1 now leans on even more heavily than before.

The ISO 10993 Series at a Glance

Infographic showing the ISO 10993 series for biological evaluation of medical devices, including ISO 10993-1, -5, -6, -7, -10, -12, -17, and -18. — The ISO 10993 series consists of multiple standards that together form a complete biological evaluation framework for medical devices.

ISO 10993-1 doesn’t stand alone — it’s the framework document for a series that covers specific test methods and evaluation categories.

Part	Covers	Status Note
ISO 10993-1	Overall evaluation and testing within a risk management process	Sixth edition (2025) now partially recognized by FDA
ISO 10993-5	In vitro cytotoxicity	2009 edition, still current
ISO 10993-6	Local effects after implantation	Updated 2026 edition
ISO 10993-7	Ethylene oxide sterilization residuals	Updated 2026 edition
ISO 10993-10	Irritation and skin sensitization	2021 edition
ISO 10993-12	Sample preparation and reference materials	2021 edition, amended 2025
ISO 10993-17	Toxicological risk assessment of device constituents	2023 edition, amended 2025
ISO 10993-18	Chemical characterization of materials	2020 edition, amended 2022

Most common finding: Manufacturers cite ISO 10993-5 or -10 correctly but leave the ISO 10993-1 reference in their design history file pointing to the 2018 edition without any documented rationale for why. If your BEP hasn’t been revisited since the 2025 edition published, that’s the first thing to check.

If your device is sterilized and you haven’t looked at how the 2026 edition of ISO 10993-7 interacts with your sterilization validation, our sterilization standards overview walks through ISO 11135, 11137, 17665, and 11607 alongside it.

What Changed in ISO 10993-1:2025

The sixth edition isn’t a light refresh. ISO’s technical committee reorganized the standard and changed its title to explicitly align with the ISO 14971 risk management framework. The practical changes:

More detailed guidance on calculating exposure duration — including how to treat foreseeable misuse, such as a device used longer than its labeled duration.
Expanded guidance on device characterization and biological hazard identification, intended to reduce reliance on generic test batteries.
Terminology aligned with ISO 14971, so if your team already knows that standard, the 2025 edition should read more consistently — though NAMSA and other industry commentators note there isn’t yet a technical report equivalent to ISO/TR 24971 to guide interpretation of the new edition.

Here’s how the two editions compare on the points that matter most for your Biological Evaluation Plan:

Topic	2018 Edition	2025 Edition
Risk Management Integration	Referenced ISO 14971	More explicitly aligned throughout
Exposure Duration	Limited guidance	Expanded methodology for calculating duration, including foreseeable misuse
Biological Hazard Identification	Less detailed	Expanded guidance on device characterization and hazard identification
Risk Estimation	Different treatment	New Clause 6.9 (excluded by FDA)

If you are preparing a Biological Evaluation Plan for a new device → start by confirming which edition your FDA reviewer or notified body expects to see referenced, since adoption isn’t uniform across regions. The EU has generally moved faster toward treating the 2025 edition as state of the art. Manufacturers should verify current adoption expectations directly with their notified body and applicable competent authorities, since implementation timing varies and is subject to change.

One shift worth flagging for regulatory teams building out a modern BEP: chemical characterization under ISO 10993-18 is playing a larger role than it used to. Rather than defaulting to a blanket biological test matrix for every device, more manufacturers are leaning on thorough chemical characterization data — extractables and leachables profiles, material composition analysis — to justify a narrower, risk-based testing strategy. ISO 10993-1:2025’s expanded hazard identification guidance reinforces this shift. A well-documented ISO 10993-18 characterization can reduce redundant biological testing, but only if the chemistry-driven rationale is documented clearly enough to withstand a reviewer’s scrutiny.

Comparison graphic showing the major differences between ISO 10993-1:2018 and ISO 10993-1:2025 for biological evaluation of medical devices. — The 2025 edition places greater emphasis on risk management integration, biological hazard identification, and exposure assessment.

ISO 10993 FDA Recognition: What’s Excluded and Why

🔑 Key FDA Takeaway FDA recognizes ISO 10993-1:2025, but excludes:

The “consumer products” language in Clause 6.5.11.3

Clause 6.9 on biological risk estimation

Manufacturers should document alternative justification using FDA guidance and ISO 14971.

On May 25, 2026, FDA updated its Recognized Consensus Standards database (Recognition No. 2-313) to include ISO 10993-1:2025 — but not in full. Two specific exclusions matter for your submissions:

The phrase “consumer products or” in Clause 6.5.11.3. This clause addresses low-risk, intact-skin-contacting devices. The standard allows manufacturers to point to a material’s history of safe use in consumer products as justification for reduced testing. FDA excluded this because it conflicts with Attachment G of its 2023 biocompatibility guidance, which defines specific materials with an accepted history of use — a consumer product history alone doesn’t automatically satisfy FDA’s expectations.
Clause 6.9 on biological risk estimation. FDA determined this clause conflicts with the risk estimation approach already established in the FDA-recognized ISO 14971:2019. Sponsors can’t rely on Clause 6.9 to claim conformity in a submission.

If you are under customer or notified body pressure to update your BEP quickly → prioritize reviewing these two clauses first. They’re the specific areas where citing the 2025 edition alone won’t satisfy FDA, and you’ll need to document your justification through existing FDA guidance instead.

Partial recognition means you cannot submit a clean Declaration of Conformity to the full 2025 edition. Your submission documentation needs to call out the partial recognition explicitly and show how you’re addressing the excluded clauses — silence on this point is what generates additional information requests.

Workflow illustrating FDA partial recognition of ISO 10993-1:2025 and the documentation required for excluded clauses during medical device submissions. — FDA recognizes ISO 10993-1:2025 with specific exclusions, requiring manufacturers to document alternative regulatory justifications.

Do You Need to Retest Already-Cleared Devices?

This is the objection I hear most from teams looking at this update: does a new edition mean I have to redo my biocompatibility testing on devices that already have clearance?

No — not automatically. FDA’s recognition of a newer edition doesn’t retroactively invalidate data or clearances based on the 2018 edition. If you already hold clearance under the 2018 edition → you don’t need to retest existing devices. What you do need is a documented rationale, at your next design change or periodic review, for why your BEP still reflects sound risk management even though a newer edition exists. That’s a documentation and justification exercise, not a lab exercise.

Where this becomes a live issue is new submissions and significant design changes going forward — those are where reviewers will expect to see the current edition addressed.

Where Biocompatibility Fits Into Your ISO 13485 QMS

Biocompatibility data doesn’t live in isolation — it’s part of your design and development file under ISO 13485, and it feeds directly into your risk management file under ISO 14971. If your ISO 13485 documentation structure doesn’t have a clear place for biological evaluation plans, reports, and the rationale behind edition changes, that’s a gap worth closing before your next internal audit — not after a nonconformance is written.

This also connects to supplier controls. If a component supplier’s certificate of conformance references ISO 10993-1 by edition, your incoming inspection and supplier qualification process needs a mechanism to catch when that reference goes stale — the same principle covered in our guide on common mistakes in ISO 13485 QMS implementation.

And if you’re managing devices sold in both the US and EU, the edition-adoption gap between FDA and the EU regulatory framework is one more reason to keep your MDR vs ISO 13485 documentation aligned rather than treating them as separate tracks.

👉 If your biological evaluation documentation hasn’t been reviewed since the 2025 edition published, don’t wait for a finding to tell you. Check where your QMS documentation actually stands →

Quick Audit Checklist

✅ Confirm which edition of ISO 10993-1 your current BEP references, and whether that matches what your reviewer or notified body expects
✅ Check whether your device’s biocompatibility justification relies on Clause 6.5.11.3 (consumer product history) or Clause 6.9 (risk estimation) — both need alternative justification for FDA submissions
✅ Verify supplier certificates of conformance cite current standard editions, not stale references
✅ Confirm your risk management file cross-references your BEP consistently ✅ If your device is sterilized, check the 2026 editions of ISO 10993-6 and -7 against your current validation data ⚠️ Don’t assume “FDA recognized” means “fully accepted” — verify the Supplementary Information Sheet for any standard before citing it as a full Declaration of Conformity

FAQ

What is biocompatibility testing for medical devices?

Biocompatibility testing evaluates whether the materials in a medical device, and the way those materials contact the body, could cause an unacceptable biological response. It covers areas like cytotoxicity, sensitization, irritation, and systemic toxicity, selected based on the device’s contact type and duration.

What is ISO 10993-1, and do I need to comply with it?

ISO 10993-1 is the framework standard that governs how you plan and justify a biological evaluation within a risk management process. If your device contacts the body directly or indirectly, FDA and most global regulators expect your biocompatibility strategy to follow its structure, even where full conformity isn’t feasible.

What changed between ISO 10993-1:2018 and ISO 10993-1:2025?

The 2025 edition reorganized the standard to align more closely with ISO 14971, added detailed guidance on calculating exposure duration and identifying biological hazards, and updated terminology throughout.

Has the FDA recognized ISO 10993-1:2025?

Yes, as of May 25, 2026, but only partially. FDA excluded the “consumer products” language in Clause 6.5.11.3 and all of Clause 6.9 on biological risk estimation, both of which conflict with existing FDA guidance and the FDA-recognized ISO 14971:2019.

Do I need to retest devices already cleared under the 2018 edition?

No. Existing clearances aren’t invalidated by a newer edition. You do need a documented rationale for your current approach at your next design change or periodic review.

Which parts of the ISO 10993 series apply to my device?

That depends on your device’s contact type (surface, external communicating, or implant) and contact duration (limited, prolonged, or permanent). ISO 10993-1 provides the matrix for selecting relevant parts of the series based on those two factors. We’ll be covering that contact-duration matrix in detail in an upcoming guide.

Is ISO 10993 the same as ISO 13485?

No. ISO 13485 governs your overall quality management system for medical devices. ISO 10993 is a series specifically about biological evaluation, and its outputs — your BEP and test reports — become part of the design and development records your ISO 13485 QMS requires you to maintain.

Where do I purchase ISO 10993 standards?

Individual parts and bundled packages are available through the ANSI Webstore, which also serves international buyers and offers documents in multiple languages. The ISO.org catalog describes each part but is not the recommended purchase channel.

📥 Free Resources

ISO 9001 Roadmap — step-by-step implementation guide for manufacturers building or improving a quality management system.
Manufacturing Compliance Checklist — practical compliance reference covering key ISO, OSHA, and quality requirements for production environments.
Supplier Quality Checklist — evaluation tool for assessing supplier quality controls and flow-down compliance before audits or new contracts.
ISO 13485 Gap Assessment Checklist — free checklist for medical device manufacturers assessing their QMS against ISO 13485 requirements, including where biocompatibility documentation fits.
AS9100 Rev D Gap Assessment Checklist — 74-item clause-by-clause checklist for aerospace suppliers assessing their QMS before certification.

Not Sure What to Do Next?

🔹 Still researching how the 2025 edition affects your device category? Start with our breakdown of risk management under ISO 14971 — biocompatibility evaluation doesn’t stand apart from it anymore.

🔹 Ready to check where your documentation actually stands? Run the ISO 13485 Gap Assessment Checklist before your next audit or submission, not after.

🔹 Need to purchase the current standard? ISO 10993-1:2025 — ANSI Webstore, or get the full biological evaluation package bundled at roughly 45% off individual pricing if you’re assembling multiple parts of the series. Use code CC2026 for an additional 5% off through December 31, 2026.

The Standards Navigator will keep tracking how FDA recognition evolves on this standard as updates are published.

Documentation Gaps Don’t Show Up Until Someone’s Looking For Them

Teams that treat biocompatibility as a one-time lab exercise are the ones caught off guard when a standard’s edition changes underneath them. Teams that treat it as a living part of their design and risk management file catch the mismatch at their next internal review, not during an FDA question round — and it’s usually a citation that didn’t keep up, not the underlying science, that stalls a submission.

The Standards Navigator tracks these regulatory shifts as they happen — not months later when the transition deadline is already close. If ISO 10993-1:2025 affects your device, this is a good window to revisit your documentation rationale while the timeline is still in your control.

👉 Get updates on medical device compliance and biocompatibility standard changes
👉 Be first to access new gap assessment checklists and documentation tools for ISO 13485 and ISO 14971

Subscribe below to stay ahead.

The Standards Navigator — Industrial Compliance. Clearly Explained.

Risk Management in Medical Devices: How to Build an ISO 14971-Compliant Process in 2026

Medical device risk management is the thread that connects every element of your ISO 13485 QMS — and the first place an auditor looks. This guide covers all five stages of the ISO 14971:2019 process, required documentation at each step, how to set defensible acceptability criteria, and the most common findings in notified body and FDA audits.

A step-by-step implementation guide for medical device manufacturers building or strengthening a risk management framework under ISO 14971:2019 and ISO 13485:2016

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

Your Risk Management File Is the First Thing an Auditor Opens

Not your QMS manual. Not your SOPs. Your risk management file.

That is where a notified body auditor or FDA inspector starts — because risk management in medical devices is the thread that connects every other element of your quality system. If your risk file is thin, incomplete, or disconnected from your design and production controls, the rest of your documentation will not save you.

Most medical device companies understand that ISO 14971:2019 requires a risk management process. Fewer understand what that process actually looks like when it is fully implemented — the outputs required, the decisions that must be documented, and the points where ISO 13485:2016 Clause 7.1 and ISO 14971 intersect in ways that catch teams off guard during audits.

This article walks through the complete risk management process for medical devices: what ISO 14971 requires at each stage, how those requirements connect to your QMS, and where most teams fall short.

I have spent 25 years in heavy industrial manufacturing running quality systems under ISO 9001, managing nonconformances, and building risk-based approaches to process control. When I transitioned into the ISO 13485 space, the discipline was familiar — but the regulatory stakes were different. In manufacturing, a process failure costs you time and scrap. In medical devices, the same gap in your risk file can cost you a 483 observation, a warning letter, or a market withdrawal. The rigor required is not optional, and it is not theoretical. Every output described in this article is something auditors actively look for.

Before you read further: If you have not yet assessed where your current risk management process stands against ISO 14971:2019 requirements, start there. A structured gap assessment takes less time than an audit finding.

📥 Download the ISO 13485 Gap Assessment Checklist — Free checklist for medical device manufacturers assessing their QMS against ISO 13485 requirements, including risk management obligations under Clause 7.1.

In This Guide

What ISO 14971:2019 actually requires — the full process, not just the outputs
How ISO 13485 Clause 7.1 connects to your risk management file
The five stages of the ISO 14971 process with required documentation at each step
How to set acceptable risk criteria — the decision most teams get wrong
Post-production surveillance and why it feeds back into your risk file
The most common audit findings in risk management reviews
Training options for teams building or rebuilding a compliant process

👉 Start Here: Top Resources for Medical Device Risk Management

If you are building or rebuilding your risk management process, these are the resources that will move you fastest:

ISO 14971:2019 — ANSI Webstore — The current edition of the standard. Required reading for anyone responsible for a device risk management file. Use code CC2026 for 5% off at checkout.
ISO 13485 Training — BSI Group — BSI offers ISO 13485 implementation and auditor training that covers risk management integration in depth.
ISO 13485 Training — ISOQAR — ISOQAR provides training and certification services for ISO 13485, with risk-based thinking woven throughout their courses.

What ISO 14971:2019 Requires

ISO 14971 risk management lifecycle infographic showing the seven stages of risk management in medical devices and required outputs from planning through post-production surveillance. — A visual overview of the ISO 14971 risk management lifecycle and the documentation outputs auditors expect to see.

ISO 14971:2019 is the international standard for the application of risk management to medical devices. It applies throughout the full device lifecycle — from concept through post-market surveillance.

The standard does not prescribe a specific risk analysis method. It does not tell you to use FMEA, FTA, or a risk matrix of a particular format. What it requires is a documented, systematic process that produces specific outputs at each stage.

The core framework in ISO 14971:2019 includes:

Stage	What ISO 14971 Requires
Risk management plan	Define scope, responsibilities, criteria for risk acceptability, and review activities
Risk analysis	Identify intended use, reasonably foreseeable misuse, and associated hazards and hazardous situations
Risk evaluation	Compare estimated risk against criteria — determine if risk reduction is required
Risk control	Select and implement controls; verify effectiveness; assess residual risk and any new risks introduced
Benefit-risk analysis	Where residual risk remains, evaluate whether the overall benefit outweighs remaining risk
Risk management report	Summarize the process and confirm residual risks are acceptable
Post-production information	Collect and review field data; feed findings back into risk management

Every output — the plan, the analysis, the controls, the report — must be captured in a risk management file.

How ISO 13485 Clause 7.1 Connects

ISO 13485:2016 Clause 7.1 requires that your organization document risk management requirements throughout product realization. This is not a standalone obligation — it is a QMS-level requirement that ties your risk file to your design controls, supplier management, production processes, and CAPA system.

The key connection points:

Design and development (Clause 7.3): Risk management inputs and outputs must be included in design planning. Design reviews, verification, and validation activities must all reference and be consistent with the risk management file.

Purchasing and supplier controls (Clause 7.4): Supplier-introduced risks must be identified and addressed. If a supplier failure creates a patient hazard, that scenario belongs in your risk analysis.

Production and service provision (Clause 7.5): Special processes — sterilization, labeling, software-dependent controls — require risk-based validation. Your risk file should identify where these controls are critical and what happens if they fail.

CAPA (Clause 8.5): Post-market findings, complaints, and nonconformances are data sources for your risk management process. A complaint that reveals a hazardous situation not previously identified in your risk analysis must trigger a risk file update.

Most common finding: Auditors frequently cite a disconnect between the CAPA system and the risk management file — complaints and CAPAs are processed and closed without evaluating whether the risk file needs to be updated.

If you are evaluating your current QMS against these connection points, the gap assessment checklist above covers all of them.

The Five-Stage Risk Management Process

Stage 1: Risk Management Plan

Your risk management plan is not a form — it is a governing document for the entire risk process for a specific device. It must define:

The scope of activities (which device, which lifecycle phases)
Roles and responsibilities for risk management activities
Requirements for review of risk management activities
Criteria for risk acceptability — what level of residual risk is acceptable and on what basis

The last item is where most teams take shortcuts. Acceptability criteria cannot simply reference “ALARP” or “as low as reasonably practicable” without defining what that means for your device and patient population. Auditors will push on this.

Stage 2: Risk Analysis

Risk analysis begins with a thorough description of the device — its intended use, intended users, and reasonably foreseeable misuse. From there, you identify:

Hazards (potential sources of harm)
Hazardous situations (circumstances in which people could be exposed to a hazard)
Harm sequences (how the hazardous situation leads to harm)

ISO 14971 Annex C provides a non-exhaustive list of hazard categories: energy hazards, biological hazards, environmental hazards, hazards related to incorrect output, and others. Use it as a prompt, not as a complete list.

Common analysis methods include FMEA (Failure Mode and Effects Analysis), FTA (Fault Tree Analysis), and HAZOP. Most device teams use FMEA as the primary tool. None of these methods is required by the standard — but whatever method you use must be documented and consistently applied.

Stage 3: Risk Evaluation

Once you have estimated the probability and severity of each harm, you evaluate whether each risk requires reduction. This evaluation is made against the acceptability criteria defined in your risk management plan.

If a risk exceeds your acceptable threshold, risk reduction is required. If it falls below the threshold, you still need to document the evaluation decision — not just assume silence means acceptable.

📥 If you are not confident your current risk file covers these evaluation decisions consistently, download the ISO 13485 Gap Assessment Checklist and work through Section 7 — it maps directly to these requirements.

Stage 4: Risk Control

ISO 14971 infographic showing the risk control hierarchy and residual risk evaluation process for medical device risk management. — ISO 14971 requires organizations to prioritize design controls first, verify effectiveness, and document residual risk decisions before closing risk.

ISO 14971 requires you to follow a three-level hierarchy when selecting controls:

Inherent safety by design — eliminate or reduce the hazard through design choices
Protective measures — add guards, alarms, or protective barriers in the device or manufacturing process
Information for safety — labeling, instructions for use, training requirements

You must implement controls in this order of preference. You cannot jump to warnings and labeling as your primary control if a design solution is practicable.

After implementing each control:

Verify the control was implemented as intended
Verify the control is effective at reducing risk
Assess whether the control introduces any new hazards
Re-evaluate residual risk after all controls are applied

Stage 5: Residual Risk and Benefit-Risk Analysis

After controls are in place, residual risk will remain for most devices. If residual risk exceeds your acceptability criteria even after all practicable controls have been applied, you must perform a benefit-risk analysis: does the clinical benefit of the device outweigh the remaining risk?

This analysis must be documented. “We believe the benefit outweighs the risk” is not documentation. The analysis must reference clinical evidence, intended use, and the nature and magnitude of remaining harm.

Setting Acceptable Risk Criteria

This is the decision most risk management teams get wrong, and it is the one auditors examine most carefully.

Your risk acceptability criteria must be:

Defined before you begin risk analysis — not after you have already seen your risk estimates
Based on relevant policy, standards, and guidance applicable to your device category
Specific enough to make clear decisions — a matrix with defined severity and probability ranges, not a narrative statement

What Auditors See	What They Want to See
“We aim to reduce risk ALARP”	A defined matrix with probability/severity scales and explicit acceptable/unacceptable zones
Criteria defined after the analysis was completed	Criteria established in the risk management plan before analysis began
One set of criteria applied across all device types	Criteria appropriate to the specific device and patient population
No documented basis for the criteria chosen	Reference to applicable guidance documents (IMDRF, EU MDR, FDA guidance)

Reference points that support defensible criteria include FDA guidance on risk management for device software, IMDRF guidance documents, and the introductory notes in ISO 14971:2019 itself.

Risk Control Options and Residual Risk

One of the most common gaps in risk files is incomplete residual risk documentation. Teams identify hazards, apply controls, and then fail to document the post-control risk estimate.

Every control must have:

A documented implementation record (the control was actually applied)
A verification record (the control works as intended)
A post-control risk re-estimate (residual probability × severity)
An evaluation of residual risk against acceptability criteria

If your controls introduce new hazards — which software controls, sterilization processes, and combination products frequently do — those new hazards must be analyzed through the full process. There is no shortcut.

If you are preparing for your first ISO 13485 certification audit, verify that every risk control in your file has all four of these elements documented before your Stage 1 audit. Incomplete residual risk documentation is one of the most common major nonconformances found in initial certification audits.

BSI Group offers ISO 13485 implementation training that specifically addresses risk file documentation structure, including residual risk evaluation requirements. ISOQAR provides similar training with a certification pathway.

The Risk Management File

The risk management file is not a single document. It is a collection of records that demonstrates the complete risk management process was followed for a specific device. What it must contain:

Risk management plan
Risk analysis outputs (hazard list, probability/severity estimates)
Risk evaluation records (acceptability decisions)
Risk control records (implementation, verification, new hazard assessment)
Residual risk evaluation
Benefit-risk analysis (where required)
Risk management report
Post-production information review records

The risk management report is the capstone document. It confirms that the risk management plan was followed, all residual risks are acceptable, and appropriate methods were used to obtain relevant production and post-production information.

Your risk management file must be maintained and updated throughout the product lifecycle. It is not a one-time certification exercise.

ISO 14971 risk management file infographic showing required records and how the file integrates with ISO 13485 quality management requirements. — The risk management file is the central evidence package that demonstrates ISO 14971 compliance across the medical device lifecycle.

Post-Production Information and Surveillance

ISO 14971 Clause 9 requires a systematic process to collect and review post-production information. This includes:

Customer complaints and feedback
Field service and repair reports
Medical device reports (MDRs) and vigilance reports
Published literature and adverse event databases
Post-market clinical data

This information must be evaluated to determine whether it:

Indicates previously unidentified hazards
Changes the estimated probability or severity of a known harm
Invalidates earlier risk control decisions

If it does, your risk file must be updated. Your CAPA process must have a defined trigger for escalating post-market findings to the risk management team.

Most common finding: Post-market surveillance is treated as a regulatory reporting obligation rather than a risk management input. Complaints are processed through CAPA, but the risk file is never reviewed against complaint trends. This is a major nonconformance under both ISO 13485 Clause 8.2.1 and ISO 14971 Clause 9.

Common Audit Findings in Risk Management Reviews

These are the findings that appear most frequently in ISO 13485 and EU MDR notified body audits:

✅ Incomplete risk analysis scope — Reasonably foreseeable misuse not identified or analyzed. Risk analysis covers intended use only.

⚠️ Acceptability criteria defined after the analysis — Criteria were back-filled to match the estimates, rather than established as the decision framework before analysis began.

⚠️ Missing residual risk evaluation — Controls were implemented and verified, but no post-control risk estimate was documented.

✅ Disconnected CAPA and risk file — Complaints and CAPAs processed and closed without triggering a risk file review.

⚠️ Labeling used as the primary control — Instructions for use are cited as the risk control when a design solution was practicable.

✅ Risk file not maintained post-launch — The risk file was complete at certification but has not been updated since. Design changes, new complaint data, and field findings are not reflected.

⚠️ No benefit-risk analysis where residual risk is above acceptability threshold — Teams acknowledge residual risk exceeds their criteria but do not formally document the benefit-risk justification.

Training for Your Risk Management Team

Risk management competence is a requirement, not a preference. Your team members responsible for risk management activities must be trained — and that training must be documented.

Both BSI Group and ISOQAR offer ISO 13485 training that covers risk management integration. BSI also offers a dedicated Risk Management — Requirements (ISO 14971) e-learning course for teams who need focused training on the standard itself.

If you are already certified under ISO 13485 and preparing for a surveillance audit:

If your risk team has not been formally trained on ISO 14971:2019 since the 2019 edition was published, now is the time to close that gap. The 2019 edition introduced changes to state-of-the-art requirements and manufacturer benefit-risk responsibilities that differ from the 2007 edition.

If you are building your QMS from scratch and need structured implementation support across all 8 clauses:

If you are evaluating implementation support options, review what documentation a compliant ISO 13485 QMS requires before investing in training. It will help you scope what your team actually needs to build.

FAQ

What is the difference between ISO 14971 and ISO 13485 for risk management?

ISO 13485:2016 Clause 7.1 requires that risk management be applied throughout product realization. ISO 14971:2019 is the standard that defines how to do it — the process, the required outputs, and the documentation. ISO 13485 tells you that you must manage risk. ISO 14971 tells you how. Most medical device manufacturers must comply with both.

Is ISO 14971 mandatory?

ISO 14971 is not directly mandated by law in most markets, but it is referenced as a harmonized standard under the EU MDR 2017/745 and EU IVDR 2017/746. For FDA-regulated devices in the US, compliance with ISO 14971 supports conformance with 21 CFR Part 820 design controls requirements. As a practical matter, no notified body or FDA inspection team will accept a risk management process that does not align with ISO 14971.

What is a risk management file?

A risk management file is the complete collection of records that documents the risk management process for a specific device. It includes the risk management plan, risk analysis outputs, evaluation records, control records, residual risk documentation, benefit-risk analysis (where required), the risk management report, and post-production surveillance records. The file must be maintained and updated throughout the device lifecycle.

How often should a risk management file be updated?

Your risk management file must be updated whenever there is a change to the device, its intended use, or new information that could affect risk estimates — including complaints, adverse events, published literature, or design changes. Many organizations establish a formal periodic review (annually or at defined product lifecycle milestones) as part of their post-market surveillance process.

What risk analysis methods does ISO 14971 require?

ISO 14971 does not mandate a specific method. FMEA, FTA, HAZOP, and preliminary hazard analysis are all acceptable approaches. What the standard requires is that the method be documented, systematic, and capable of identifying hazards and estimating risk. Most medical device manufacturers use FMEA as their primary method.

What is the difference between a hazard, a hazardous situation, and harm in ISO 14971?

A hazard is a potential source of harm — for example, excessive electrical energy in a device. A hazardous situation is a circumstance in which people, property, or the environment could be exposed to the hazard — for example, a patient contact point that can carry excessive current under a specific failure condition. Harm is the physical injury or damage to health that results. ISO 14971 requires that you trace the full sequence from hazard to harm for each risk identified.

How does ISO 14971 relate to CAPA in ISO 13485?

Your CAPA process should have a defined trigger for escalating complaints, adverse events, and nonconformances to the risk management team for evaluation. If a post-market finding reveals a previously unidentified hazard or changes the estimated probability of an existing risk, your risk file must be updated. Closing a CAPA without evaluating its implications for the risk file is one of the most common major findings in ISO 13485 surveillance audits.

What changed in ISO 14971:2019 compared to the 2007 edition?

ISO 14971:2019 introduced several substantive changes: clarified the concept of state-of-the-art and how manufacturers must use it; expanded and clarified the benefit-risk analysis process; updated the overall residual risk evaluation process; and revised the structure of the standard to align with ISO management system high-level structure conventions. Teams trained only on the 2007 edition may have gaps in their current process.

📥 Free Resources

These tools are available at no cost to support your ISO 13485 and risk management implementation:

ISO 13485 Gap Assessment Checklist — Free checklist for medical device manufacturers assessing their QMS against ISO 13485 requirements, including risk management obligations under Clause 7.1
ISO 9001 Roadmap — Step-by-step implementation guide for manufacturers building or improving a quality management system
Manufacturing Compliance Checklist — Practical compliance reference covering key ISO, OSHA, and quality requirements for production environments
Supplier Quality Checklist — Evaluation tool for assessing supplier quality controls and flow-down compliance before audits or new contracts
AS9100 Rev D Gap Assessment Checklist — 74-item clause-by-clause checklist for aerospace suppliers assessing their QMS before certification

Not Sure What to Do Next?

🔹 Still building your understanding of ISO 13485 requirements? Start with the ISO 13485 Implementation Roadmap — it walks through all 8 clauses and how they connect before you invest in building documentation.

🔹 Ready to implement and need training for your risk management team? Both BSI Group and ISOQAR offer ISO 13485 training with risk management integration. BSI also has a dedicated ISO 14971 e-learning course.

🔹 Need to purchase ISO 14971:2019 for your quality team? Get it from the ANSI Webstore — use code CC2026 for 5% off through December 31, 2026.

Risk management is not a documentation exercise you complete before certification and revisit every few years. It is the living framework that keeps your device safe, your quality system defensible, and your audits clean. Build it right from the start — and maintain it like the regulatory asset it is.

The Standards Navigator covers ISO 13485, ISO 14971, FDA requirements, and medical device quality management in depth. Use the resources above to move from gap to compliant.

Stay Current on Medical Device Compliance

Most teams that struggle with ISO 13485 audits are not missing knowledge — they are missing a system for keeping their risk files, documentation, and compliance processes current as requirements evolve.

Organizations that pass surveillance audits consistently have one thing in common: their quality teams are not surprised by what auditors look for. They have a process for staying ahead of requirement changes, notified body expectations, and post-market obligations.

The Standards Navigator covers ISO 13485, ISO 14971, FDA QMSR, and medical device compliance requirements in plain language for quality professionals and regulatory teams.

👉 Get updates on the medical device compliance cluster — new articles, requirement changes, and implementation guidance delivered directly to your inbox.

👉 Be first to access new free resources, including the ISO 13485 Documentation Starter Kit when it launches.

Subscribe below to stay ahead.

The Standards Navigator — Industrial Compliance. Clearly Explained.

Medical Device Compliance Standards: What Manufacturers Need to Know in 2026

Medical device manufacturers face a layered compliance framework — ISO 13485, ISO 14971, FDA QMSR, and EU MDR each impose specific requirements that must work together as an integrated system. This guide explains the core standards, how they interact, and what manufacturers need to prioritize at each stage of the compliance process.

The regulatory framework every medical device manufacturer must understand before the first audit

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

The Compliance Gap That Gets Medical Device Manufacturers in Trouble

Most medical device manufacturers don’t fail audits because they ignored the requirements. They fail because they didn’t understand how the requirements connect — and which standards they were actually obligated to meet.

The medical device compliance standards landscape is layered. ISO 13485 sets the QMS framework. ISO 14971 governs risk management. FDA regulations run parallel to international standards and don’t always align. Supplier controls, sterilization validation, design controls, and labeling each carry their own standard reference. A manufacturer who treats these as independent checkboxes instead of an integrated system is building toward an audit finding — or worse, a product recall.

The stakes are not abstract. The FDA issued 483 observations totaling thousands of findings in the medical device sector last year. Most cited documentation gaps, inadequate CAPA processes, or failure to meet design control requirements — all areas governed by the standards covered in this guide.

I’ve worked in quality systems that span heavy industrial, energy, and manufacturing environments — and the pattern I’ve seen across every sector is the same: organizations that struggle with audits are usually managing compliance requirements in silos. In the medical device world, that problem is amplified because the regulatory framework is both more complex and less forgiving than most industrial standards. Getting the structure right before your first audit is not optional — it’s the difference between certification and a warning letter.

Before you map your compliance requirements, download the ISO 13485 Gap Assessment Checklist — it walks you through every clause so you can identify exactly where your QMS falls short before an auditor does → ISO 13485 Gap Assessment Checklist

In This Guide:

The core standards every medical device manufacturer must know
How ISO 13485, ISO 14971, and FDA regulations interact
US vs. EU regulatory requirements compared
Supplier control and special process standards
Decision-stage guidance: what to prioritize based on where you are in the compliance process

👉 Start Here — Top Resources

Buy ISO 13485:2016 — ANSI Webstore — the official QMS standard for medical device manufacturers (use code CC2026 for 5% off)
ISO 13485 Training — BSI Group — training courses and certification services for ISO 13485
Buy ISO 14971:2019 — ANSI Webstore — risk management standard required alongside ISO 13485

The Core Standard: ISO 13485:2016

ISO 13485:2016 infographic showing clause structure and comparison of ISO 13485 versus ISO 9001 requirements for medical device quality management systems. — A visual breakdown of ISO 13485:2016 requirements and how they differ from ISO 9001 for medical device manufacturers.

ISO 13485:2016 is the international standard for quality management systems specific to medical device manufacturers and their supply chains. It is the foundation of medical device compliance worldwide.

ISO 13485 is not simply ISO 9001 with medical device language added. The two standards share structural similarities through the harmonized high-level clause structure, but ISO 13485 imposes stricter requirements in several critical areas ISO 9001 leaves to organizational discretion:

Requirement Area	ISO 9001:2015	ISO 13485:2016
Risk management	Risk-based thinking (general)	Formal risk management required (links to ISO 14971)
Design controls	Required	More prescriptive — validation, verification, design transfer
CAPA	Required	More detailed — specific investigation and effectiveness checks
Regulatory requirements	Not addressed	Explicitly required — must identify and meet applicable regs
Sterile product controls	Not addressed	Specific controls for sterile devices
Supplier controls	Required	More stringent — supplier qualification and monitoring
Document and record retention	Not specified	Specific retention periods tied to device lifetime

If you are ISO 9001 certified and entering the medical device market, you are not starting from scratch — but you are adding significant requirements. The gap is larger than most manufacturers expect.

If you need the standard itself, ISO 13485:2016 is available through the ANSI Webstore — use code CC2026 for 5% off through December 31, 2026.

Most common finding: Inadequate document control — specifically, failure to control the review and approval of documents and maintain records of changes. ISO 13485 Clause 4.2 is one of the most frequently cited areas in FDA 483 observations.

Risk Management: ISO 14971:2019

ISO 14971 is the international standard for risk management applied to medical devices. It is not optional if you are manufacturing medical devices — ISO 13485 explicitly requires you to apply risk management throughout the product lifecycle, and ISO 14971 is the recognized method for doing it.

ISO 14971:2019 defines the process for:

Identifying hazards associated with a medical device
Estimating and evaluating associated risks
Controlling those risks
Monitoring the effectiveness of controls

The relationship between ISO 13485 and ISO 14971 is not optional. ISO 13485 Clause 7.1 requires organizations to establish risk management requirements for product realization. ISO 14971 is the standard that defines what “proper” risk management looks like. Auditors will look for evidence that your risk management file connects directly to your design controls, production processes, and post-market surveillance activities.

ISO 14971 vs. ISO 13485 — understanding how they interact is one of the most common questions from manufacturers building a QMS for the first time.

If your risk management files exist independently of your design control documentation — that is an audit finding waiting to happen. Most teams miss the linkage between hazard identification in the risk management file and the verification/validation activities in the design history file.

Run your gap assessment before you go further — most QMS gaps in medical device companies trace back to missing connections between ISO 14971 risk files and ISO 13485 design controls: ISO 13485 Gap Assessment Checklist

US Regulatory Requirements: FDA QMSR and 21 CFR Part 820

US medical device manufacturers operate under FDA jurisdiction. The Quality Management System Regulation (QMSR), which took effect February 2, 2026, replaced the legacy Quality System Regulation (QSR) under 21 CFR Part 820.

The QMSR represents a significant shift: it incorporates ISO 13485:2016 by reference as the baseline for device QMS requirements. This means FDA-regulated manufacturers who are ISO 13485 certified are closer to QMSR compliance than they were under the old QSR — but important differences remain.

Area	ISO 13485:2016	FDA QMSR (2026)
Scope	International	US market devices only
Complaints	Required	Required + specific MDR reporting timelines
Corrections and removals	Addressed in CAPA	Specific FDA reporting requirements (21 CFR Part 806)
UDI	Not addressed	Required for most device classes
Electronic records	Not specified	21 CFR Part 11 compliance required
Third-party audits	Required for ISO 13485 certification	FDA inspections — not third-party certification

Understanding the relationship between FDA QSR and ISO 13485 is essential for US manufacturers — the two frameworks are now more aligned than before, but they are not identical.

If you are selling devices in the US market, FDA QMSR compliance is a legal requirement, not a voluntary certification. ISO 13485 certification does not satisfy FDA obligations — it demonstrates QMS capability but does not substitute for an FDA inspection.

Comparison infographic showing US FDA QMSR and EU MDR regulatory pathways for medical device manufacturers and ISO 13485 quality system requirements. — A side-by-side comparison of US FDA QMSR and EU MDR pathways showing how medical device compliance differs across global markets.

EU Requirements: MDR and CE Marking

Selling medical devices in the European Union requires CE marking under the EU Medical Device Regulation (MDR 2017/745), which replaced the Medical Device Directive (MDD) and came into full effect in 2021. The transition deadline for legacy MDD-certified devices has been extended but enforcement has tightened significantly.

Key MDR requirements relevant to QMS:

MDR Requirement	Connection to ISO 13485
Technical documentation	Design history file / DHF requirements
Clinical evaluation	Post-market clinical follow-up (PMCF)
Unique Device Identification (UDI)	Traceability requirements
Post-market surveillance (PMS)	Customer feedback and complaint monitoring
Notified Body audit	ISO 13485 certification is typically required
Person Responsible for Regulatory Compliance (PRRC)	Management responsibility — ISO 13485 Clause 5

The MDR is more prescriptive than ISO 13485 in clinical evidence requirements. If you are exporting to the EU, your clinical evaluation report and post-market surveillance plan must meet MDR requirements that go beyond what ISO 13485 explicitly requires.

If you are selling in both the US and EU markets, you are managing two regulatory frameworks simultaneously. This is where a well-structured ISO 13485 QMS becomes particularly valuable — it provides the common foundation that both frameworks build on.

Supplier Controls and Special Process Standards

ISO 13485 Clause 7.4 imposes stricter supplier control requirements than most manufacturers new to the medical device space expect. You are not simply verifying that a supplier has a quality system — you are responsible for ensuring that purchased products and services meet specified requirements and that critical suppliers are evaluated, approved, and monitored.

For medical device manufacturers, supplier controls must address:

Supplier qualification — documented criteria for evaluation and approval
Incoming inspection — defined acceptance criteria for purchased product
Critical supplier monitoring — ongoing performance data, not just initial qualification
Supplier audits — for high-risk or critical component suppliers
Flow-down requirements — pushing your quality requirements into the supply chain

Special processes — sterilization, biocompatibility testing, coating, welding on implantable components — require additional validation documentation. The relevant standards include:

Process	Standard Reference
Sterilization (EO, radiation, steam)	ISO 11135, ISO 11137, ISO 17665
Biocompatibility	ISO 10993 series
Packaging validation	ASTM F2132, ISO 11607
Software validation	IEC 62304
Electrical safety	IEC 60601 series

These are not optional for manufacturers of the relevant device types. If your device is sterilized, you need sterilization validation documentation. If it contacts patient tissue, you need biocompatibility data. Gaps in special process validation are among the most serious findings an FDA inspector or Notified Body auditor can cite.

Design Controls and Validation Standards

ISO 13485 design controls infographic showing the Design History File process from inputs through outputs, verification, validation, and design transfer. — A visual guide to the ISO 13485 design controls process and how design inputs become validated, production-ready medical devices.

Design controls are where ISO 13485 certification and FDA compliance intersect most directly. ISO 13485 Clause 7.3 requires a structured design and development process covering:

Design and development planning
Design inputs (requirements)
Design outputs (specifications)
Design review at defined stages
Design verification (does it meet inputs?)
Design validation (does it meet user needs?)
Design transfer (can it be manufactured consistently?)
Design changes (controlled and documented)

The design history file (DHF) is the physical record of this entire process. It is the first thing an FDA inspector or Notified Body auditor will request. Manufacturers who build their DHF as a collection of unconnected documents — rather than as a traceable record linking inputs to outputs to verification to validation — create significant risk for themselves.

If you are new to building a medical device QMS and need a structured path through these requirements, the ISO 13485 Implementation Roadmap on The Standards Navigator covers the full sequence from gap assessment through certification.

BSI Group offers ISO 13485 training covering both requirements understanding and implementation — useful for teams building their first medical device QMS or transitioning from a general ISO 9001 system.

Labeling and Traceability Standards

Labeling compliance is a specific, frequently cited area in FDA 483 observations. Under both FDA QMSR and MDR requirements, device labeling must meet defined content and format requirements — and the label must be controlled as a quality record.

Key labeling standards and requirements:

ISO 15223-1 — symbols used in medical device labeling (required for EU MDR compliance)
21 CFR Part 801 — FDA labeling requirements for US devices
UDI requirements — FDA requires Unique Device Identification on most device labels, with submission to the GUDID database

Traceability connects directly to your CAPA and complaint handling processes. If a complaint involves a specific lot or device unit, your traceability records must be sufficient to identify affected products, investigate the root cause, and determine corrective action scope. ISO 13485 Clause 7.5.9 addresses traceability explicitly — and auditors will test it.

How the Standards Work Together

Layered medical device compliance standards infographic showing ISO 13485 as the foundation with ISO 14971, FDA QMSR, EU MDR, supplier controls, CAPA, and traceability requirements. — A visual framework showing how ISO 13485, FDA QMSR, EU MDR, and supporting standards connect into an integrated medical device compliance system.

The most important thing to understand about medical device compliance is that these standards are not independent — they form an integrated system. Here is how they connect:

Standard	Role in the System
ISO 13485:2016	QMS framework — the backbone that everything else connects to
ISO 14971:2019	Risk management process — required by ISO 13485, referenced throughout
FDA QMSR	US regulatory layer — builds on ISO 13485, adds FDA-specific requirements
EU MDR	EU regulatory layer — requires ISO 13485 certification via Notified Body
IEC 62304	Software lifecycle — required if your device includes software
ISO 10993	Biocompatibility — required for patient-contacting devices
ISO 15223	Labeling symbols — required for EU MDR labeling compliance

A manufacturer who has ISO 13485 certification, a complete ISO 14971 risk management file, and solid FDA QMSR documentation has built the framework that all additional standards layer onto. The common mistake is treating each standard as a separate compliance project rather than building the integrated system first.

If you are deciding between prioritizing FDA QMSR or ISO 13485 certification first: in most cases, building to ISO 13485 gives you the QMS foundation that both US and EU regulatory compliance require. The ISO 13485 Documentation Requirements article covers what your QMS documentation set must include.

Quick Compliance Checklist

Use this as a starting reference — not a substitute for a clause-by-clause gap assessment.

✅ ISO 13485:2016 obtained and QMS scope defined
✅ Risk management procedure in place referencing ISO 14971
✅ Design controls documented — inputs, outputs, verification, validation, transfer
✅ CAPA process established with effectiveness verification
✅ Supplier qualification and monitoring program documented
✅ Document and record control procedures in place with defined retention periods
✅ Internal audit program scheduled and resourced
✅ Management review process defined and conducted
✅ Complaint handling and MDR/vigilance reporting process established
✅ UDI requirements evaluated and implemented where applicable
✅ Applicable special process validations identified and documented
✅ Labeling reviewed against ISO 15223 (EU) and 21 CFR Part 801 (US)

⚠️ If you cannot check most of these — complete a formal gap assessment before committing to a certification timeline.

FAQ

Is ISO 13485 certification required to sell medical devices?

ISO 13485 certification is not legally required by US law — the FDA requires QMSR compliance, not ISO 13485 certification specifically. However, ISO 13485 certification is required to sell devices in the EU under MDR, and it is increasingly required by OEM customers and contract manufacturers as a condition of doing business. Most manufacturers targeting both markets pursue certification.

How is ISO 13485 different from ISO 9001?

ISO 13485 is a sector-specific standard derived from ISO 9001 but with significantly stricter requirements in risk management, design controls, CAPA, supplier controls, and regulatory compliance. It does not include the continual improvement emphasis that ISO 9001 requires — instead it focuses on consistent compliance with regulatory requirements. A detailed comparison is covered here.

Do I need ISO 14971 if I am ISO 13485 certified?

Yes. ISO 13485 explicitly requires risk management throughout the product lifecycle and references ISO 14971 as the applicable method. You are not ISO 13485 compliant if your risk management process does not meet ISO 14971 requirements. The two standards work together — you cannot separate them.

What is the FDA QMSR and how is it different from the old QSR?

The Quality Management System Regulation (QMSR) took effect February 2, 2026 and replaced 21 CFR Part 820 (the Quality System Regulation). The QMSR incorporates ISO 13485:2016 by reference, making it more aligned with the international standard. Key differences remain around FDA-specific reporting requirements, UDI obligations, and 21 CFR Part 11 electronic records requirements. A full breakdown of FDA QSR vs ISO 13485 is here.

How long does it take to get ISO 13485 certified?

For a manufacturer building a QMS from scratch, 12–18 months is a realistic timeline. Organizations with an existing ISO 9001 QMS can often close the gap in 6–12 months, depending on how many medical device-specific requirements need to be added. The ISO 13485 Implementation Roadmap covers the full timeline in detail.

What is a Notified Body and do I need one?

A Notified Body is an organization designated by EU member states to assess conformity of medical devices under the MDR. If you are seeking CE marking for Class IIa, IIb, or Class III devices, you must engage a Notified Body — they conduct the audits that verify ISO 13485 compliance and technical documentation. BSI Group is one of the major Notified Bodies offering both training and certification services.

What are the most common ISO 13485 audit findings?

The most frequently cited areas include: inadequate document and record control (Clause 4.2), incomplete CAPA processes with missing effectiveness verification (Clause 8.5.2), insufficient supplier qualification documentation (Clause 7.4), and gaps in design control records — particularly missing design verification and validation evidence (Clause 7.3). Common mistakes in ISO 13485 QMS implementation covers these in detail.

Do my suppliers need to be ISO 13485 certified?

Not necessarily — but you are responsible for ensuring purchased product meets specifications regardless. Whether a supplier needs ISO 13485 certification depends on their criticality and what they supply. Critical component suppliers and contract manufacturers of finished devices are typically expected to be certified. Commodity suppliers may only require documented incoming inspection.

📥 Free Resources

ISO 13485 Gap Assessment Checklist — free checklist for medical device manufacturers assessing their QMS against ISO 13485 requirements — medical device articles only

ISO 9001 Roadmap — step-by-step implementation guide for manufacturers building or improving a quality management system

Manufacturing Compliance Checklist — practical compliance reference covering key ISO, OSHA, and quality requirements for production environments

Supplier Quality Checklist — evaluation tool for assessing supplier quality controls and flow-down compliance before audits or new contracts

AS9100 Rev D Gap Assessment Checklist — 74-item clause-by-clause checklist for aerospace suppliers assessing their QMS before certification

Not Sure What to Do Next?

🔹 Still researching your compliance requirements? Start with a gap assessment against ISO 13485 before you invest in implementation. Download the free ISO 13485 Gap Assessment Checklist — it maps every clause so you know exactly where you stand.

🔹 Ready to build your QMS? ISO 13485 training through BSI Group covers requirements, implementation, and internal auditor training — the right sequence for a team building their first medical device QMS.

🔹 Need the standard itself? Buy ISO 13485:2016 through the ANSI Webstore — use code CC2026 for 5% off through December 31, 2026. International buyers can purchase in multiple languages.

Medical device compliance is not a single standard — it is a framework of interconnected requirements that must be built and maintained as a system. Understanding how ISO 13485, ISO 14971, FDA QMSR, and EU MDR relate to each other is the first step toward building a QMS that holds up under audit. The Standards Navigator covers each of these standards in depth — start with the resources above and build from there.

Stay Current on Medical Device Compliance

Regulatory changes in the medical device space don’t slow down. FDA QMSR took effect in 2026. EU MDR enforcement is intensifying. ISO 14971 continues to be misapplied by manufacturers who treat risk management as a documentation exercise rather than an integrated process.

Organizations that keep pace with these changes have one thing in common — they’re not waiting for an audit finding to tell them something changed. The ones that struggle are managing compliance reactively, updating their QMS only when a customer or inspector forces the issue.

The Standards Navigator covers ISO 13485, ISO 14971, FDA regulatory requirements, and the full medical device compliance framework — from standard purchase through certification and ongoing surveillance.

👉 Get updates when new medical device compliance articles publish
👉 Be first to access the ISO 13485 Documentation Kit when it launches

Subscribe below to stay ahead.

The Standards Navigator — Industrial Compliance. Clearly Explained.

ISO 13485 Implementation Roadmap: How to Build a Compliant Medical Device QMS in 2026

ISO 13485:2016 is now US federal law under the FDA QMSR, making a compliant medical device QMS mandatory rather than optional. This roadmap walks manufacturers through a seven-phase implementation — from gap assessment and scope through risk management, documentation, CAPA, and certification — covering both the international certification path and FDA inspection readiness for US manufacturers building from the ground up.

A step-by-step guide to implementing ISO 13485:2016 — from gap assessment to certification and FDA QMSR readiness

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

Building a Medical Device QMS Is No Longer Optional in the United States

For years, ISO 13485 sat in a strange position for US manufacturers. It was the global benchmark for medical device quality management — required to sell in the EU, Canada, and most of the world — but inside the United States it was voluntary. You complied with FDA’s Quality System Regulation, and ISO 13485 was a nice-to-have for export.

That changed on February 2, 2026. FDA’s Quality Management System Regulation (QMSR) took effect, replacing the old Quality System Regulation and incorporating ISO 13485:2016 by reference directly into 21 CFR Part 820. The practical effect is blunt: ISO 13485:2016 is now part of US federal law. FDA inspections are conducted against it. The standard you could once ignore at home is now the framework your inspector arrives with.

So whether you are a US manufacturer preparing for your first QMSR-aligned FDA inspection, or an international supplier chasing your first ISO 13485 certificate to unlock the EU market, you face the same task: build a quality management system that survives outside scrutiny. This roadmap walks you through it — clause by clause, phase by phase — from the day you decide to start to the day a registrar or an FDA investigator walks through the door.

This ISO 13485 implementation roadmap is a long article because building a medical device QMS is a long project. Use the table of contents to jump to where you are.

Before you build anything, find out where you actually stand. Most teams overestimate how compliant their existing processes are — and discover the gaps during the certification audit or FDA inspection, when fixing them is expensive and the clock is running. Run a clause-by-clause check against ISO 13485:2016 first.

👉 Download the free ISO 13485 Gap Assessment Checklist and benchmark your QMS in an afternoon, before you commit budget to implementation.

In This Guide

Why ISO 13485 implementation looks different in 2026 (QMSR, EU reforms)
The realistic timeline and cost of a full implementation
A seven-phase roadmap from gap assessment to certificate
How risk management (ISO 14971) and design controls fit into the QMS
The documentation you actually need — and where teams over-build
Internal audit, management review, and Stage 1 / Stage 2 audit preparation
FDA QMSR inspection readiness for US manufacturers
The mistakes that fail audits — and how to avoid them

👉 Start Here (Top Resources)

If you are implementing ISO 13485 from scratch, these are the three resources that move the project fastest:

Build your documentation without a consultant. A complete, pre-written ISO 13485 documentation kit gives you the quality manual, procedures, and records templates structured to the standard — so you spend your time tailoring, not drafting from a blank page. 👉 See the ISO 13485 documentation kits at 9001Simplified
Get the official standard. You cannot implement a clause you have not read. Buy ISO 13485:2016 from the ANSI Webstore — use code CC2026 for 5% off through December 31, 2026. ANSI serves international buyers and offers standards in multiple languages.
Train your internal team. Your management representative and internal auditors need formal training. BSI Group offers ISO 13485 training courses spanning awareness through lead auditor.

What Makes 2026 Different

ISO 13485:2016 is still the current edition — and it will be for a while. ISO postponed the next revision deliberately to let the 2016 edition “bed in,” with a new version not expected before roughly 2028–2029. So the standard you implement today is the standard you will operate under for years. That stability is good news: it means your implementation work has a long shelf life.

What has shifted is the regulatory context around the standard.

In the United States, the QMSR is the headline. FDA now incorporates ISO 13485:2016 into 21 CFR Part 820, layered with a handful of FDA-specific additions — labeling, UDI, and certain record and definition provisions — that go beyond the ISO text. A critical nuance: the QMSR is “version locked” to the 2016 edition. Future ISO 13485 revisions will not automatically apply in the US unless FDA initiates new rulemaking. Certification to ISO 13485 is still not legally required in the US — FDA inspects you directly — but building your QMS to the standard is now the most direct path to QMSR compliance.

In the European Union, the pressure point is notified body capacity, not the standard itself. EU Implementing Regulation 2026/977, published in May 2026 and applying from February 25, 2027, finally imposes hard maximum timelines on notified bodies — 30 days to review an application and sign a contract, 120 days for the QMS audit, 90 days for product verification, and 20 days to issue the certificate, with capped clock-stops and transparent quotations. For manufacturers, the message is that the certification path is becoming more predictable, but you still need a clean, audit-ready QMS to take advantage of it.

One more 2026 wrinkle worth flagging if your devices touch biocompatibility: FDA’s recognition of the sixth edition of ISO 10993-1 is partial. Notably, FDA does not recognize Clause 6.9 on biological risk estimation, holding that it conflicts with the recognized risk management standard ISO 14971:2019. If your risk files cite ISO 10993-1 wholesale, that is now a deficiency-letter risk in US submissions. Keep biological risk inside the ISO 14971 framework. We cover biocompatibility in depth separately — for this roadmap, just know that your risk management process is the anchor, not the 10993 series.

If you sell only in the US → build to ISO 13485:2016 for QMSR compliance and skip certification unless a customer demands it. If you sell internationally → you need an actual ISO 13485 certificate from an accredited registrar, so plan for a Stage 1 / Stage 2 audit. If you sell in both markets → build one QMS to ISO 13485:2016 and bolt on the FDA-specific QMSR additions; do not run two parallel systems.

QMSR vs ISO 13485 at a Glance

The two frameworks now share a core, but they are not identical. This is where US and international readers diverge — and where a single well-built QMS can serve both.

Dimension	ISO 13485:2016	FDA QMSR (21 CFR Part 820)
Legal status	Voluntary international standard	Mandatory US federal regulation
Core requirements	The full ISO 13485 QMS	Incorporates ISO 13485:2016 by reference
Proof of compliance	Certificate from accredited registrar	FDA inspection — no certificate issued
Added requirements	None beyond the standard	Labeling, UDI, certain records & definitions
Risk management	References ISO 14971	Requires ISO 14971 framework; rejects ISO 10993-1 Clause 6.9
Version handling	ISO may revise (~2028–2029)	“Version locked” to the 2016 edition
Who needs it	Anyone selling internationally	Any device manufacturer marketing in the US

For the full treatment, see our dedicated FDA QSR vs ISO 13485 comparison.

Timeline and Cost: What to Expect

A realistic ISO 13485 implementation runs 6 to 12 months for a small-to-mid-size manufacturer building from a limited starting point. Companies already operating a mature ISO 9001 system or a legacy QSR-based system can move faster; companies starting from informal processes should plan for the full year.

ISO 13485 implementation timeline infographic showing a phased 6 to 12 month roadmap for medical device manufacturers progressing from gap assessment through certification. — A visual roadmap showing a realistic ISO 13485 implementation timeline from assessment through certification readiness.

Phase	Typical duration	What drives it
Gap assessment & scope	2–4 weeks	Size of the gap between current practice and the standard
Process & documentation build	8–16 weeks	Whether you draft from scratch or start from templates
Implementation & operation	8–12 weeks	You need real records, not just documents — audits want evidence
Internal audit & management review	3–4 weeks	Must be complete before a registrar will proceed to Stage 2
Certification (Stage 1 + Stage 2)	6–10 weeks	Registrar scheduling and any nonconformity closure

On cost, the single biggest variable is whether you hire a consultant to draft your system or build it yourself from a structured template. Consultant-led implementations commonly run $15,000–$50,000+ depending on device class and company size. A template-driven build can cut the documentation labor dramatically. For a full breakdown, see our guide on how much ISO 13485 certification costs.

Phase 1 — Foundation: Scope, Standard, and Leadership Commitment

Everything downstream depends on getting three things right at the start.

Define your QMS scope. ISO 13485 lets you exclude certain requirements — for example, design and development (Clause 7.3) if you are a contract manufacturer building to a customer’s design. But exclusions must be justified and documented, and you cannot exclude something just because it is inconvenient. Map which clauses apply to your role: manufacturer, specification developer, contract manufacturer, sterilization provider, or importer. Your scope statement is the first thing a registrar reads and the boundary an FDA investigator works within.

Acquire and read the standard. This sounds obvious and gets skipped constantly. You cannot delegate compliance with a document nobody on the team has read end to end. Buy the official ISO 13485:2016 text from the ANSI Webstore — apply coupon CC2026 for 5% off through the end of 2026 — and have your management representative work through it clause by clause. If you also need the risk management standard, ISO 14971:2019 is available there too. ANSI’s catalog covers international buyers and multiple languages, which matters if your QMS spans sites.

Secure genuine leadership commitment. Clause 5 puts top management on the hook — quality policy, quality objectives, resource allocation, and management review are not delegable to a quality manager working in isolation. The fastest implementations have an executive sponsor who clears roadblocks. The ones that stall have a quality team trying to impose a system the leadership treats as paperwork.

If you are a contract manufacturer → document your design and development exclusion now, with justification, before you build the rest of the system around it.

⚠️ Common pitfall: Claiming a Clause 7.3 exclusion you can’t defend. If your team does any design input — even tweaking a customer’s spec for manufacturability — a registrar may reject the exclusion and you’ll be retrofitting design controls mid-project. Decide your true scope honestly before you build.

Most ISO 13485 projects don’t fail on the standard — they fail on documentation that nobody can find, follow, or defend in an audit. Before you write a single procedure, make sure you know which records the standard actually requires.

👉 Run the gap assessment and map your existing documents against the clauses — it turns “we think we’re covered” into a defensible list.

Phase 2 — Plan: Processes, Roles, and Competence

ISO 13485 is a process-based standard. Before documentation, map your actual processes and how they connect — the “sequence and interaction” the standard requires.

Identify your core processes. At minimum: management processes (planning, review, resourcing), product realization (design, purchasing, production, servicing), and support processes (document control, records, CAPA, internal audit). For each, define inputs, outputs, owners, and the records that prove it ran.

Appoint a management representative. Clause 5.5.2 requires a member of management responsible for the QMS. This person owns the system, reports its performance to leadership, and is typically the registrar’s main point of contact.

Plan competence and training. Clause 6.2 requires that personnel performing work affecting product quality are competent — with records to prove it. This includes your internal auditors, who must be trained and independent of the areas they audit. Formal training shortens the learning curve here; BSI Group’s ISO 13485 course catalog runs from awareness through lead auditor, and the lead-auditor tier is what equips your internal audit program to find problems before the registrar does. For audit methodology itself, note that the underlying guidance standard, ISO 19011, was updated to a 2026 edition in May 2026 — worth referencing when you write your internal audit procedure.

⚠️ Common pitfall: Treating internal auditor “independence” as a formality. Having someone audit their own department is one of the most common nonconformities — and it quietly undermines every finding that audit produces. Cross-train auditors so no one reviews work they own.

Phase 3 — Risk Management and Design Controls

This is where ISO 13485 separates itself from ISO 9001, and where the most consequential implementation decisions live.

Risk management is the spine. ISO 13485 threads risk-based thinking through the entire product lifecycle, and it leans on ISO 14971:2019 as the method. You need a risk management process, a risk management file for each device or device family, and evidence that risk controls are verified and monitored in production and post-market. As noted earlier, keep biological risk inside this ISO 14971 framework rather than importing a separate scoring approach — that alignment is exactly what FDA expects under the QMSR.

Design controls (Clause 7.3) apply if you develop devices. This is the discipline FDA investigators scrutinize hardest, because design failures are where patients get hurt. You need:

Design control element	What it requires
Design and development planning	A documented plan with stages, reviews, and responsibilities
Design inputs	Requirements derived from intended use, user needs, and regulation
Design outputs	Specifications that can be verified against inputs
Design review	Formal reviews at planned stages with independent reviewers
Design verification	Evidence outputs meet inputs
Design validation	Evidence the device meets user needs in actual or simulated use
Design transfer	Controlled handoff to production
Design changes	Controlled, reviewed, and documented changes
Design history file (DHF)	The complete record of the above

If you are a US manufacturer, the QMSR keeps design controls firmly in play — they map directly onto the ISO 13485 Clause 7.3 requirements, which is one reason a single ISO-aligned system now serves both purposes.

If you are preparing your first device submission → build the risk management file and design history file in parallel with the QMS, not after. Auditors and investigators expect to see them populated, not planned.

⚠️ Common pitfall: Building the risk file as a one-time document for the submission, then never touching it again. Risk management is a living, lifecycle requirement — production and post-market data have to feed back into it. A risk file frozen at launch is a finding waiting to happen.

Phase 4 — Build the Documentation

Now you write the system. ISO 13485 expects a defined documentation hierarchy: a quality manual, documented procedures, work instructions, forms, and the records they generate.

ISO 13485 documentation architecture infographic showing the five-layer quality management documentation hierarchy from quality manual through records. — A visual breakdown of the five documentation layers used to build and maintain an ISO 13485 quality management system.

The required documents. ISO 13485:2016 explicitly requires certain documented procedures — document control, record control, management review, internal audit, control of nonconforming product, CAPA, and several product-realization procedures among them. A medical device file (technical documentation) is required for each device type. Our breakdown of ISO 13485 documentation requirements lists exactly what the standard mandates versus what is optional.

Where teams over-build. The most common documentation mistake is writing procedures more detailed and rigid than the operation can actually follow. Every sentence in a procedure is a commitment an auditor can hold you to. If your procedure says calibration happens every 90 days and a record shows 95, that is a nonconformity you created with your own words. Write to what you do; improve what you do separately.

Start from a structured template, not a blank page. Drafting an entire ISO 13485 documentation set from scratch is where 6-month projects become 12-month projects. A complete documentation kit gives you the quality manual, every required procedure, and the records templates already structured to the clauses — so your team spends its hours tailoring language to your operation instead of reinventing the architecture of a QMS.

👉 See what’s included in the 9001Simplified ISO 13485 documentation kit — it is the no-consultant route most small manufacturers should evaluate first.

Set up document and record control before you generate volume. Clauses 4.2.4 and 4.2.5 require controlled documents and controlled records. Get the control mechanism — versioning, approval, retention, retrieval — working before you have hundreds of documents to retrofit.

⚠️ Common pitfall: Over-documenting. Teams write procedures so detailed and rigid that the floor can’t actually follow them — then every deviation from their own paperwork becomes a nonconformity. Document what you genuinely do, keep procedures lean, and push the specifics down into work instructions where they’re easier to change.

Phase 5 — Implement and Operate

A documented QMS proves nothing. Auditors and investigators want records that show the system ran.

This is the phase teams underestimate. You can write a CAPA procedure in a day; demonstrating that CAPA actually works requires real CAPAs opened, investigated, and closed over weeks. Plan for an operating period — typically 8 to 12 weeks minimum — where the system runs and generates genuine evidence: training records, calibration records, completed reviews, supplier evaluations, nonconformance reports, and CAPA records.

A registrar will not progress to a certification audit, and an FDA investigator will not be satisfied, by documents alone. Both want to trace a process from requirement to record to outcome. Build that evidence trail before you invite anyone to inspect it.

If you are under customer pressure to certify quickly → start operating the system in parallel with finishing documentation, so your evidence trail is already accumulating when the documents are signed off.

⚠️ Common pitfall: Booking the certification audit before the system has actually run. A registrar can tell the difference between a QMS that has operated for three months and one that generated all its records last week. Backdated or thin evidence is the fastest way to turn a Stage 2 audit into a list of nonconformities.

Phase 6 — CAPA, Supplier Controls, and Production Controls

Three areas generate the most audit findings and FDA 483 observations. Get them right and you de-risk the entire certification.

CAPA (Corrective and Preventive Action). This is the single most-cited area in medical device QMS audits. A weak CAPA system — actions opened and never closed, root causes not actually identified, effectiveness never verified — signals to an auditor that the whole system is decorative. Your CAPA process must show genuine root cause analysis, defined actions, and verified effectiveness. Our deep dive on CAPA requirements in ISO 13485 covers the failure modes in detail.

Supplier and purchasing controls (Clause 7.4). You are accountable for what your suppliers provide. You need defined supplier evaluation criteria, approved-supplier records, and controls proportionate to the risk the purchased product carries. Flow your quality requirements down in writing — handshake arrangements do not survive audits.

Production and process controls (Clauses 7.5). This includes process validation for any process whose output cannot be fully verified by later inspection — sterilization and certain welding or molding processes are classic examples — plus identification, traceability, and handling of product. Cleanliness, contamination control, and installation/servicing requirements apply where relevant to your device.

A documentation kit accelerates this layer too. The CAPA log, supplier evaluation forms, nonconformance records, and validation templates are exactly the high-stakes documents you do not want to invent under deadline.

👉 A structured kit gives you defensible templates for all three areas so your effort goes into running the processes, not formatting the paperwork.

Avoid the recurring traps documented in our guide to common mistakes in ISO 13485 QMS implementation — most failures are predictable.

⚠️ Common pitfall: Closing CAPAs without verifying effectiveness. “We retrained the operator” is not a closed CAPA — it’s an action with no proof it worked. Auditors reopen these constantly. Every CAPA needs a defined effectiveness check and evidence it passed before you close it.

Phase 7 — Internal Audit, Management Review, and Certification

Before any external party inspects you, inspect yourself.

Internal audit (Clause 8.2.4). Conduct a full internal audit of your QMS against ISO 13485 using trained, independent auditors. This is your dress rehearsal — the audit that finds problems while you still control the timeline and the narrative. Document findings, open CAPAs, and close them.

Management review (Clause 5.6). Top management formally reviews QMS performance against defined inputs — audit results, customer feedback, process performance, CAPA status, and more — and produces documented outputs and decisions. Registrars treat a missing or hollow management review as a serious gap.

The certification audit (international path). An accredited registrar conducts a two-stage audit:

Stage	Focus	Outcome
Stage 1	Documentation review and readiness	Confirms the system is ready for Stage 2; identifies gaps
Stage 2	On-site implementation audit	Verifies the system operates as documented; raises any nonconformities

Close any nonconformities, and the registrar issues your certificate — typically valid for three years with annual surveillance audits. Choosing an accredited registrar matters; verify accreditation through bodies like ANAB or the relevant IAF member. Our guide to the best ISO certification bodies walks through selection.

⚠️ Common pitfall: Running a hollow management review to check the box. A review that doesn’t actually examine audit results, CAPA status, and process performance — and produce real decisions — is treated by registrars as a serious gap, because it signals leadership isn’t engaged. Make it substantive, and keep the minutes.

FDA QMSR Inspection Readiness

If you are a US manufacturer, your “certification audit” may instead be an FDA inspection — and the bar is the QMSR, which now runs on ISO 13485:2016 plus FDA’s additions.

Practical readiness steps:

Map ISO 13485 to the QMSR additions. Most of your ISO-aligned system satisfies Part 820 directly. Layer in the FDA-specific requirements — labeling and packaging controls, UDI, and certain record and complaint-handling provisions — that exceed the ISO text.
Keep your records inspection-ready, not audit-ready-once. FDA inspections are unannounced or short-notice. The evidence trail from Phase 5 has to be standing, not assembled on demand.
Treat CAPA and complaint handling as the focal points. These are where 483 observations concentrate. A clean, closed-loop CAPA system is your strongest signal of control.
Understand the relationship between the two frameworks. Our comparison of FDA QSR vs ISO 13485 explains exactly what the QMSR changed and where the frameworks now align.

For US manufacturers selling internationally, the efficient move is one ISO 13485 QMS with the QMSR additions built in — not two systems. The frameworks now overlap by design.

Quick Implementation Checklist

Use this as a high-level progress tracker. Each item maps to a phase above.

✅ QMS scope defined and exclusions justified in writing
✅ Official ISO 13485:2016 (and ISO 14971:2019) acquired and read
✅ Top management commitment secured; quality policy and objectives set
✅ Management representative appointed
✅ Core processes mapped with owners, inputs, outputs, and records
✅ Personnel competence and internal auditor training in place
✅ Risk management process and risk management file established (ISO 14971)
✅ Design controls and design history file in place (if you develop devices)
✅ Quality manual, required procedures, and record templates written
✅ Document control and record control operating before volume builds
✅ System operated long enough to generate genuine records (8–12 weeks)
✅ CAPA system demonstrably closing the loop with verified effectiveness
✅ Supplier evaluation and purchasing controls documented and flowed down
✅ Process validation completed where output can’t be fully verified
✅ Full internal audit completed; findings closed
✅ Management review conducted with documented outputs
✅ Registrar selected (international) or QMSR inspection readiness confirmed (US)
✅ Stage 1 and Stage 2 audit passed; nonconformities closed

FAQ

How long does ISO 13485 implementation take?

For a small-to-mid-size manufacturer building from a limited starting point, plan for 6 to 12 months. Companies with a mature ISO 9001 system or a legacy QSR-based system can move faster, while organizations starting from informal processes should plan for the full year. The longest single phase is usually documentation, followed by the operating period needed to generate real records.

Is ISO 13485 certification required in the United States?

No. FDA inspects US manufacturers directly against the QMSR, which incorporates ISO 13485:2016 — certification by a third-party registrar is not legally required. However, building your QMS to ISO 13485 is now the most direct path to QMSR compliance, and certification is required to sell in the EU, Canada, and most international markets. Many US manufacturers certify anyway to serve global customers and demonstrate a recognized standard of control.

What is the difference between ISO 13485 and the FDA QMSR?

The QMSR, effective February 2, 2026, replaced FDA’s old Quality System Regulation and incorporates ISO 13485:2016 by reference into 21 CFR Part 820, plus FDA-specific additions covering labeling, UDI, and certain records. The two are now largely aligned by design. The QMSR is “version locked” to the 2016 edition, so future ISO 13485 revisions will not automatically apply in the US. See our full FDA QSR vs ISO 13485 comparison for detail.

Do I need ISO 14971 to implement ISO 13485?

Effectively, yes. ISO 13485 threads risk-based thinking through the product lifecycle and relies on the methodology in ISO 14971:2019 for risk management. You need a documented risk management process and a risk management file for each device. We explain the relationship in ISO 14971 vs ISO 13485.

Can a contract manufacturer exclude design controls?

Yes, if you build strictly to a customer’s design and do not perform design and development activities. ISO 13485 permits excluding Clause 7.3, but the exclusion must be justified and documented in your QMS scope. You cannot exclude a requirement simply because it is burdensome — only because it genuinely does not apply to your role.

What causes most ISO 13485 audit findings?

CAPA weaknesses lead the list — actions that never close, root causes not genuinely identified, and effectiveness never verified. Document and record control, supplier controls, and process validation are also frequent finding areas. Our guide to common ISO 13485 QMS mistakes covers the recurring patterns.

Should I hire a consultant or use a documentation kit?

It depends on device class, internal capacity, and budget. Consultant-led implementations offer hands-on guidance but commonly run $15,000–$50,000 or more. A structured documentation kit gives you the full QMS architecture — manual, procedures, and record templates — at a fraction of that cost, so your team tailors rather than drafts from scratch. Many small manufacturers start with a kit and bring in targeted consulting only for device-specific risk and design questions.

What is ISO 13485 and who needs it?

ISO 13485 is the international quality management system standard for organizations involved in the medical device lifecycle — design, production, storage, distribution, installation, and servicing. It applies to manufacturers, specification developers, contract manufacturers, sterilization providers, and importers. Our primer, What Is ISO 13485?, covers the fundamentals.

📥 Free Resources

Practical tools to support your implementation — download what fits your project:

ISO 13485 Gap Assessment Checklist — free checklist for medical device manufacturers assessing their QMS against ISO 13485 requirements, clause by clause, before committing to implementation.
ISO 9001 Roadmap — step-by-step implementation guide for organizations building or improving a quality management system, useful if you operate an ISO 9001 base alongside 13485.
Manufacturing Compliance Checklist — practical compliance reference covering key ISO, OSHA, and quality requirements for production environments.
Supplier Quality Checklist — evaluation tool for assessing supplier quality controls and flow-down compliance before audits or new contracts.
AS9100 Rev D Gap Assessment Checklist — 74-item clause-by-clause checklist for aerospace suppliers assessing their QMS before certification, for teams operating across aerospace and medical device lines.

Not Sure What to Do Next?

Your next step depends on where you are in the project:

🔹 If you haven’t assessed your gap yet → start with the free ISO 13485 Gap Assessment Checklist. Don’t commit budget to implementation until you know the size of the gap.
🔹 If you’re ready to build documentation → evaluate a complete ISO 13485 documentation kit before paying consultant rates to draft from scratch. It is the fastest route to an audit-ready document set for most small manufacturers.
🔹 If you’re comparing the US and international paths → read FDA QSR vs ISO 13485 and how much ISO 13485 costs to scope budget and timeline before you choose.

Building an ISO 13485 QMS is a real project, but it is a known one. The clauses are fixed, the phases are sequential, and the failure modes are predictable. Move through it in order, build real evidence as you go, and inspect yourself before anyone else does — and a certification audit or FDA inspection becomes a confirmation, not a gamble. The Standards Navigator exists to make exactly this kind of industrial compliance work clear and survivable for the people who have to actually do it.

Most teams don’t fail ISO 13485 because they misunderstand the standard — they fail because they assumed they were compliant and found out during the audit. The organizations that struggle treat the QMS as paperwork to satisfy a registrar. The organizations that succeed treat it as the operating system that proves their devices are safe — and they build evidence from day one.

The Standards Navigator covers medical device compliance from QMSR readiness to risk management, CAPA, and certification — written from operational and quality management experience, not generic theory.

👉 Get updates on medical device QMS, ISO 13485, and FDA QMSR compliance
👉 Be first to access new gap assessment tools, documentation guides, and implementation resources

Subscribe below to stay ahead.

The Standards Navigator — Industrial Compliance. Clearly Explained.

Buy ISO 14971:2019 — Official PDF & Print Sources (2026 Guide)

Where to buy the official ISO 14971:2019 standard, what formats are available, how much it costs, and why purchasing from an authorized source is non-negotiable for medical device risk management — including why the superseded 2007 edition still circulating online creates real certification and regulatory risk.

Where to buy the official ISO 14971:2019 standard, what formats are available, how much it costs, and why purchasing from an authorized source is non-negotiable for medical device risk management.

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

📥 Free ISO 13485 & ISO 14971 Implementation Checklist — Confirm you have every required risk management document before your first certification audit. → [Download Free Checklist]

ISO 14971 Is No Longer Optional for Medical Device Manufacturers

ISO 14971:2019 was already the international standard for medical device risk management. Since February 2, 2026, it carries additional weight: the FDA’s Quality Management System Regulation (QMSR) incorporated ISO 13485:2016 by reference — and ISO 13485 explicitly requires risk management per ISO 14971. That means ISO 14971 is now embedded in U.S. regulatory expectations for every manufacturer subject to 21 CFR Part 820.

FDA investigators operating under Compliance Program 7382.850 are expected to use the risk management file as their inspection roadmap — following risk documentation into design controls, CAPA, supplier qualification, and post-market surveillance. If your risk management program is not built on ISO 14971, that gap will surface under QMSR inspection.

This guide covers exactly where to buy the official ISO 14971:2019 standard, what formats are available, how much it costs, and what to watch out for when purchasing.

⚠️ The QMSR compliance date has passed (February 2, 2026). Organizations that have not yet integrated ISO 14971 across their quality system are operating with a gap that FDA inspectors are actively evaluating.

In This Guide

What ISO 14971:2019 is and what changed from the 2007 edition
Which edition you need — 2019 vs 2007
Where to buy the official standard from authorized sources
Available formats — PDF, print, multi-user, and bundles
How much ISO 14971:2019 costs
Who needs to purchase the standard
What ISO 14971 does NOT include
Common purchasing mistakes to avoid
Related standards you will also need

👉 Start Here (Top Resources)

👉 Purchase the official ISO 14971:2019 standard — the current edition for all medical device risk management programs → ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off through December 31, 2026. ANSI is the official U.S. distributor of ISO standards, ensuring you receive the controlled, compliant version required for certification audits.

👉 Purchase the required companion — ISO 13485:2016 → ISO 13485:2016 — ANSI Webstore — use coupon CC2026 for 5% off. ISO 14971 cannot be implemented in isolation — it is a required companion to ISO 13485 and must be purchased and controlled as an external document within your QMS.

👉 Save up to 50% buying both standards together → ISO Standards Packages — ANSI Webstore — the most cost-effective option for organizations purchasing ISO 14971 alongside ISO 13485 and related standards.

👉 Get ISO 13485 training covering risk management requirements → BSI Group ISO 13485 Training — BSI Group is a founding member of ISO and one of the world’s largest providers of ISO training courses, recognized by certification bodies globally.

👉 Get ISO 13485 certified with an accredited certification body → ISOQAR ISO 13485 Certification — ISOQAR is a UKAS-accredited certification body, one of the most recognized in the industry for ISO 13485 certification.

What Is ISO 14971:2019?

Feature image for an ISO 14971 guide showing medical device risk management concepts, lifecycle risk controls, and the relationship between ISO 14971, ISO 13485, and FDA QMSR requirements. — ISO 14971 is the required risk management framework for medical devices, embedding risk analysis and control throughout the product lifecycle and supporting ISO 13485 and FDA QMSR compliance.

ISO 14971:2019 — Medical Devices: Application of Risk Management to Medical Devices — is the international standard defining the process for identifying hazards associated with medical devices, estimating and evaluating associated risks, controlling those risks, and monitoring the effectiveness of those controls throughout the device lifecycle.

The standard is published by the International Organization for Standardization and is recognized globally as the baseline risk management framework for medical device manufacturers. It applies to all device classes — from Class I low-risk devices through Class III implantables — and to every organization involved in the device lifecycle: manufacturers, component suppliers, contract manufacturers, and service providers.

ISO 14971 does one thing with precision: it defines a formal, documented, lifecycle-integrated process for managing risk in medical device development and manufacturing. Nothing else in the ISO 13485 framework tells you how to manage risk — that is ISO 14971’s job.

Key updates in the 2019 edition include clarified terminology aligned with ISO/IEC Guide 63, updated requirements for risk management plan documentation, strengthened requirements for production and post-production information, and enhanced guidance on benefit-risk analysis. The 2019 edition also removed references to ALARP (As Low As Reasonably Practicable) — replacing it with a more precise framework for determining risk acceptability. For the complete breakdown of what the standard requires, see What Is ISO 14971? — Complete Guide.

ISO 14971:2019 vs ISO 14971:2007 — Which Do You Need?

Situation	Edition to Purchase
New risk management program — first implementation	ISO 14971:2019
Currently using ISO 14971:2007 — planning update	ISO 14971:2019
Pursuing ISO 13485 certification	ISO 14971:2019
Subject to FDA QMSR (21 CFR Part 820)	ISO 14971:2019
EU MDR technical documentation	ISO 14971:2019
Researching risk management before committing	ISO 14971:2019

The answer in every case is ISO 14971:2019. The 2007 edition has been superseded. ISO 13485:2016 references ISO 14971 — and certification bodies audit against the current edition. The QMSR regulatory expectation is built on ISO 13485:2016, which requires current-edition conformance.

If your organization is still operating a risk management program built on ISO 14971:2007, purchasing the 2019 edition and conducting a gap assessment is your first step. The changes are substantive enough that a documented gap assessment is expected before your next certification audit.

→ ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off through December 31, 2026

Where to Buy ISO 14971:2019 — Official Sources Only

ISO standards are copyrighted intellectual property. They are not available as free downloads and must be purchased from authorized distributors. Every “free ISO 14971 PDF” circulating online is an unauthorized copy — typically an outdated 2007 edition, an incomplete document, or an altered version. Using an unauthorized copy for risk management program development introduces certification risk and potential regulatory exposure simultaneously.

Certification bodies audit against the precise wording of the current official standard. A risk management file built from an outdated or incomplete copy will generate nonconformances — costing far more in audit findings and corrective action cycles than the official document.

Provider	What You Get	Price Range	Best For	Link
ANSI Webstore	Official current edition, immediate PDF delivery, audit-accepted	$150–$200	U.S.-based organizations — official distributor, CC2026 coupon available	Buy Here
ISO.org Store	Official current edition directly from publisher	$158–$198	International buyers outside the U.S.	iso.org/store
ANSI Bundle Package	ISO 14971 + ISO 13485 + related standards	$300–$500	Organizations purchasing multiple medical device standards — significant savings	Bundle Here

Where to buy ISO standards comparison showing ANSI Webstore, ISO Store, and other resellers with pros and risks — Compare ANSI, ISO, and other sources to safely buy ISO standards for certification and compliance

ANSI Webstore is the recommended source for U.S.-based organizations. ANSI is the official U.S. distributor of ISO standards — purchasing through ANSI guarantees the current edition, complete document, licensed PDF with immediate delivery, and a recognized distributor credential accepted by all certification bodies and regulatory authorities.

→ Use coupon code CC2026 for 5% off ISO and IEC standards at the ANSI Webstore through December 31, 2026

At this point, most organizations purchasing ISO 14971 for the first time should: → Purchase the bundle including ISO 13485:2016 and ISO 14971:2019 together from ANSI Standard Packages — the savings over individual purchases typically cover the cost of training materials, and you need both documents on hand before implementation begins.

ISO 14971 Formats Available

Format	Price Range	Best For	Notes
Single-user PDF	$150–$200	Individual quality managers and risk managers	Immediate delivery, searchable — cannot be shared simultaneously
Printed copy	$170–$220	Risk management teams, controlled document environments	Useful for annotating during implementation — slightly higher cost
Multi-user license	Contact ANSI	Organizations with multiple simultaneous users	Required if multiple team members need access at the same time
Bundle with ISO 13485	$300–$500	Any organization implementing ISO 13485	Best value — you need both; bundle saves 30–50% vs individual

Single-user PDF is the most common choice for quality managers implementing risk management programs. It is immediately accessible after purchase, searchable by clause number, and sufficient for a single implementer building the risk management framework.

Important licensing rule: A single-user PDF license cannot legally be shared across your organization. If your risk management team, design engineers, and regulatory affairs personnel all need simultaneous access, a multi-user license is required. Sharing a single-user PDF via email or shared drive violates the license terms — a detail that is often overlooked during implementation and can create legal exposure.

If you are implementing both ISO 14971 and ISO 13485, purchase them as a bundle. You will need both on hand from day one of your gap assessment — and the bundle consistently saves more than the coupon alone.

→ ISO Standards Packages — Save up to 50%

How Much Does ISO 14971:2019 Cost?

Item	Typical Price	Notes
Single-user PDF	$150–$200	Standard purchase from ANSI Webstore
Printed copy	$170–$220	Physical copy for reference
Multi-user license	Varies	Contact ANSI for pricing
Bundle: ISO 14971 + ISO 13485	$300–$500	Saves 30–50% vs individual purchase
Bundle: ISO 14971 + ISO 13485 + ISO 13485 collection	$350–$600	Full medical device standards set

Use coupon CC2026 for 5% off at ANSI through December 31, 2026 → Apply at ANSI

In the context of total ISO 13485 certification costs — which range from $15,000 to $100,000+ for most organizations — the ISO 14971 standard purchase is the lowest-cost line item in your entire budget. It is also the one with the highest leverage on audit outcomes. A risk management file built from the correct current edition is foundational. Everything else in your QMS depends on it.

For the complete ISO 13485 certification cost breakdown, see How Much Does ISO 13485 Cost?

Who Needs to Purchase ISO 14971?

ISO 14971:2019 must be purchased by anyone responsible for building, implementing, auditing, or maintaining a medical device risk management program. Specifically:

Risk managers and quality managers building a risk management program from scratch or updating from ISO 14971:2007 — the standard is the only authoritative source for what the process requires. Implementing from a summary or training slide deck rather than the official document is one of the most common reasons risk management files fail certification audits.

Design engineers and product development teams at organizations with design responsibility — risk management under ISO 14971 begins at design input and runs through every design stage. Engineers performing hazard analysis, risk estimation, and risk control selection need the standard directly.

Internal auditors conducting ISO 13485 internal audits — you cannot audit risk management effectiveness against a standard you have not read. Clause 7.1, 7.3, and the full risk management integration requirements across ISO 13485 require familiarity with ISO 14971 clause requirements.

Regulatory affairs professionals preparing FDA QMSR compliance documentation or EU MDR technical files — both regulatory frameworks expect ISO 14971 conformance, and regulatory submissions are evaluated against the standard’s exact requirements.

Organizations currently certified to ISO 14971:2007 planning their 2019 edition gap assessment — purchasing the 2019 edition is step one. The gap assessment cannot be conducted without it.

If you are at this stage:

If you are a quality manager building your first ISO 14971-based risk management program → purchase ISO 14971:2019 and ISO 13485:2016 together from ANSI Standard Packages, then enroll your team in BSI Group ISO 13485 Training before documentation development begins.

If you are currently ISO 14971:2007 compliant and planning your 2019 transition → purchase the 2019 edition, conduct a documented gap assessment focused on the ALARP removal, updated risk acceptability criteria, and post-production information requirements, and update your risk management plan before your next surveillance audit.

If you are a component supplier entering the medical device supply chain → your OEM customer will require ISO 14971-aligned risk management as part of supplier qualification. Purchase the standard before your first supplier audit.

What ISO 14971 Does NOT Include

Understanding what you are not buying is as important as understanding what you are.

ISO 14971 does not provide device-specific risk acceptability criteria. The standard defines the process for determining risk acceptability — it does not tell you what the acceptable residual risk level is for your specific device. That determination is your organization’s responsibility, informed by applicable regulations, clinical data, and the state of the art.

ISO 14971 does not replace clinical evaluation. Risk management and clinical evaluation are complementary but distinct requirements under ISO 13485 and EU MDR. ISO 14971 covers the risk management process — clinical evaluation has its own standards and guidance documents.

ISO 14971 does not provide implementation templates. The standard defines requirements — your organization must build the risk management plan, hazard identification tools, risk estimation worksheets, and risk control documentation. For ready-to-use ISO 13485 QMS documentation including risk management templates, see 9001Simplified Documentation Kits. 9001Simplified provides ready-to-use documentation kits that dramatically reduce the internal labor required to build a compliant QMS from scratch.

ISO 14971 does not satisfy IEC 62304. Organizations developing medical device software need IEC 62304 — software lifecycle processes for medical devices — in addition to ISO 14971. The two standards work together but address different scopes.

Common Purchasing Mistakes to Avoid

Buying ISO 14971:2007 instead of ISO 14971:2019. The 2007 edition is superseded. Third-party sellers frequently carry outdated editions without clear disclosure. Always verify the edition year before completing a purchase. If a price seems unusually low, check the edition.

Downloading unauthorized copies. Every “free ISO 14971 PDF” found through a search engine is an unauthorized copy — typically the 2007 edition, an incomplete document, or an altered version. Using it for risk management program development introduces certification risk. The standard costs $150–$200. A major nonconformance at Stage 2 costs multiples of that in re-audit fees and timeline delays.

Purchasing without checking the edition date. Even on legitimate platforms, searching “ISO 14971” can surface the 2007 edition alongside the 2019 edition. Always confirm “ISO 14971:2019” before adding to cart.

Treating ISO 14971 as a design-only requirement. The most common QMSR and ISO 13485 gap is a risk management program that lives only in design files. Under QMSR, risk-based thinking extends across supplier qualification, production processes, CAPA, complaint handling, and post-market surveillance. Purchasing the standard is step one — reading Clauses 3, 8, and 9 in their entirety is what reveals the full scope of implementation required.

Sharing a single-user PDF with your team. A single-user license covers one user. Sharing via email or shared drive violates the license terms. If multiple team members need simultaneous access, purchase a multi-user license.

Purchasing ISO 14971 without ISO 13485. ISO 14971 does not stand alone in a medical device QMS context. It is a required companion to ISO 13485 — and you need both documents to implement either correctly. Purchase them together.

At this point, most organizations who have identified they need ISO 14971 should: → Purchase the ISO Standards Bundle including ISO 14971:2019 and ISO 13485:2016 together — this is the lowest-cost, most operationally complete starting point for any medical device risk management implementation.

Why Organizations Delay This — And What It Costs Them

The most common reason manufacturers delay purchasing ISO 14971 and building a compliant risk management program is the belief that it can be addressed “during the certification project.”

Here is what consistently happens instead:

Organizations that arrive at Stage 1 of their ISO 13485 certification audit without a documented, ISO 14971-based risk management program receive a major nonconformance — delaying Stage 2 by 3–6 months and adding $5,000–$15,000 in re-audit fees and consultant costs. The risk management file is one of the first things a certification body auditor reviews.

Under QMSR, the stakes are higher. FDA investigators under CP 7382.850 use the risk management file as their inspection roadmap. An absent or inadequate risk management program does not just generate a finding — it gives the inspector a thread to pull through design controls, CAPA, and supplier qualification simultaneously.

The organizations that move first — purchasing the standard, conducting the gap assessment, and building ISO 14971 integration across the QMS before the certification audit — consistently report shorter audit cycles, fewer findings, and lower total certification costs. The ones that treat risk management as a later step discover that it is actually the foundation everything else is audited against.

📥 Free ISO 13485 & ISO 14971 Implementation Checklist — Identify your top 5 risk management gaps before your certification audit. → [Download Free Checklist]

ISO 14971 does not operate in isolation. Organizations building a medical device QMS will need these companion standards:

Standard	Purpose	Relationship to ISO 14971	Where to Buy
ISO 13485:2016	Medical device QMS requirements	Requires ISO 14971 throughout — cannot be implemented without it	ANSI Webstore
ISO/TR 24971:2020	Guidance on ISO 14971 application	Non-mandatory companion — practical guidance on applying ISO 14971 requirements	ANSI Webstore
IEC 62304	Software lifecycle for medical devices	Complements ISO 14971 for software risk management	ANSI Webstore
ISO 9001:2015	General QMS foundation	Useful reference for organizations building ISO 13485 on an existing ISO 9001 foundation	ANSI Webstore

Organizations implementing ISO 13485 for the first time should prioritize: ISO 14971:2019 + ISO 13485:2016. These two documents together define what your QMS must do and how risk must be managed within it.

→ Save up to 50% on ISO Standards Packages — ANSI Webstore

Frequently Asked Questions

What is ISO 14971:2019?

ISO 14971:2019 is the current edition of the international standard for risk management for medical devices. It defines the process for identifying hazards associated with medical devices, estimating and evaluating risks, implementing risk controls, and monitoring effectiveness throughout the device lifecycle. It is a required companion standard to ISO 13485:2016.

Is ISO 14971 required for ISO 13485 certification?

Yes — ISO 13485 explicitly requires risk management per ISO 14971 throughout the QMS. Certification bodies audit risk management processes against ISO 14971 requirements. Under the FDA’s QMSR, ISO 14971 conformance is embedded in U.S. regulatory expectations for all manufacturers subject to 21 CFR Part 820.

What is the difference between ISO 14971:2019 and ISO 14971:2007?

The 2019 edition clarified terminology, updated the risk acceptability framework by removing ALARP references, strengthened post-production information requirements, and enhanced benefit-risk analysis guidance. Any organization currently using the 2007 edition should conduct a gap assessment and transition to the 2019 edition before their next certification audit.

Where is the best place to buy ISO 14971:2019?

The ANSI Webstore is the recommended source for U.S. organizations — it is the authorized U.S. distributor for ISO standards and guarantees the current edition. Use coupon CC2026 for 5% off through December 31, 2026. → ISO 14971:2019 — ANSI Webstore

Can I share my ISO 14971 PDF with my design team?

No — a single-user PDF license cannot be shared simultaneously. If multiple team members need access at the same time, purchase a multi-user license or individual copies. Physically sharing a printed copy sequentially is permitted.

Do I need both ISO 14971 and ISO 13485?

Yes. ISO 14971 and ISO 13485 are required companions — neither can be fully implemented without the other. ISO 13485 defines your QMS framework; ISO 14971 defines how risk must be managed within it. Purchase them together for the best value. → ISO Standards Packages — Save up to 50%

Does ISO 14971 apply to software?

ISO 14971 applies to risk management for medical devices including software as a medical device (SaMD). For the software development lifecycle specifically, IEC 62304 is the companion standard. Risk management under ISO 14971 and software lifecycle management under IEC 62304 are intended to be implemented together.

What is ISO/TR 24971?

ISO/TR 24971:2020 is a technical report providing guidance on the application of ISO 14971. It is not a requirement — it is a non-mandatory companion document offering practical interpretation and application examples. Organizations new to ISO 14971 often find it valuable alongside the standard itself.

How much does ISO 14971:2019 cost?

A single-user PDF typically costs $150–$200 from the ANSI Webstore. Use coupon CC2026 for 5% off through December 31, 2026. Bundles including ISO 14971 with ISO 13485 offer savings of 30–50% compared to individual purchases.

📥 Free Resources

👉 Free ISO 13485 & ISO 14971 Implementation Checklist — Verify every required risk management document is in place before your certification audit 👉 Manufacturing Compliance Checklist — Assess your current compliance status across quality, environmental, and safety requirements 👉 Supplier Quality Checklist — Supplier qualification requirements applicable to medical device supply chains

Not Sure What to Do Next?

◆ You need the official ISO 14971:2019 standard → ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off through December 31, 2026

◆ You need the required companion standard ISO 13485:2016 → ISO 13485:2016 — ANSI Webstore — use coupon CC2026 for 5% off

◆ You want to save buying both standards together → Save up to 50% on ISO Standards Packages — ANSI Webstore

◆ You need ISO 13485 training covering risk management requirements → BSI Group ISO 13485 Training

◆ You are ready to pursue ISO 13485 certification → ISOQAR ISO 13485 Certification

◆ You want to understand what ISO 14971 requires → What Is ISO 14971? — Complete Guide

◆ You want to understand the full FDA QMSR transition → FDA QSR vs ISO 13485: The Complete QMSR Transition Guide

◆ You want to understand how ISO 9001 and ISO 13485 differ → ISO 9001 vs ISO 13485 — Key Differences

◆ You want to understand what ISO 13485 requires → What Is ISO 13485? — Complete Guide

◆ You want to understand certification costs → How Much Does ISO 13485 Cost? → ISO Certification Cost Calculator

◆ You want to choose the right certification body → Best ISO Certification Bodies — Ranked & Reviewed

Still figuring out where to start?

If you are not ready to purchase yet — that is normal. ISO 14971 implementation decisions typically take 2–4 weeks from first research to commitment as organizations assess their current risk management program against what certification auditors expect.

The best next step for most organizations at this stage: → Download the free ISO 13485 & ISO 14971 Implementation Checklist — it takes 20 minutes and tells you exactly where your gaps are before you spend anything.

📥 [Download Free Checklist]

The Standard That Makes Everything Else Auditable

ISO 14971 is not a box to check. It is the document that makes every other part of your medical device QMS auditable — design controls, CAPA, supplier qualification, complaint handling, and post-market surveillance all connect back to the risk management file when a certification auditor or FDA investigator starts pulling threads.

Organizations that purchase the official standard, read it completely, and build their risk management program against its actual requirements consistently report fewer findings, shorter audit cycles, and lower total certification costs. The ones that work from summaries, training slides, or outdated editions discover those shortcuts at the worst possible moment.

The standard costs $150–$200. A failed Stage 2 audit costs multiples of that. Buy the official edition.

At The Standards Navigator, complex standards are translated into practical, real-world guidance you can act on.

👉 Get updates on new standards, implementation strategies, and compliance insights 👉 Be first to access new guides, tools, and checklists

Subscribe below to stay ahead.

ISO 14971 vs ISO 13485: What’s the Difference and How Do They Work Together? (2026 Guide)

ISO 13485 requires risk management throughout the quality management system. ISO 14971 defines exactly how that risk management must be conducted. This guide covers the precise differences between the two standards, where they integrate clause by clause, and what the FDA’s QMSR means for both.

Last Updated: May 2026

ISO 13485 requires risk management. ISO 14971 defines how to do it. Understanding the precise relationship between these two standards — and what it means under the FDA’s QMSR — is the difference between a QMS that holds up under inspection and one that doesn’t.

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

📋 Free Download: ISO 13485 Gap Assessment Checklist Identify your compliance gaps before your first audit — 64 items across 7 sections including ISO 14971 risk management integration and all four FDA QMSR bridge requirements. Download Free Checklist

ISO 13485 Tells You to Manage Risk. ISO 14971 Tells You How.

That single sentence is the most important thing to understand about the relationship between these two standards — and it’s the part most manufacturers either misread or oversimplify.

ISO 13485:2016 is a quality management system standard. It requires risk-based thinking throughout the QMS — in design and development planning, production controls, supplier controls, complaint handling, and post-market surveillance. It references ISO 14971 in a note to Clause 7.1. But it does not specify how risk management must be conducted. It tells you risk management is required. ISO 14971 tells you how to do it.

ISO 14971:2019 is a risk management standard. It provides the structured framework — hazard identification, risk estimation, risk evaluation, risk control, overall residual risk evaluation, risk management review, and post-production monitoring — that gives ISO 13485’s risk management requirements their practical content.

Together they form the twin pillars of medical device quality and safety assurance. Neither is complete without the other for a manufacturer operating in any major regulated market. And under the FDA’s Quality Management System Regulation (QMSR), effective February 2, 2026, the relationship between the two standards now carries federal regulatory weight.

In This Guide

What ISO 13485 covers and what it requires on risk
What ISO 14971 covers and what it adds
The key differences between the two standards
The precise points where ISO 13485 references ISO 14971
The important nuance about whether ISO 14971 is truly mandatory
How the FDA QMSR changes the practical answer to that question
How to implement both standards together
Which standard to buy first and why
Frequently asked questions

✅ Start Here (Top Resources)

📋 Buy ISO 13485:2016 (official standard) → ANSI Webstore — ANSI is the official U.S. distributor of ISO standards, ensuring you receive the controlled, compliant version required for certification audits. Use coupon CC2026 for 5% off.

📋 Buy ISO 14971:2019 (required companion) → ANSI Webstore — Purchase both standards together for maximum savings. Use coupon CC2026 for 5% off.

📋 Save buying both standards → ISO Standards Bundles — Up to 50% Off — Purchasing ISO 13485 and ISO 14971 as a bundle through the ANSI Webstore saves significantly compared to individual purchases.

📋 Get ISO 13485 trained before implementation → BSI Group ISO 13485 Training — BSI Group is a founding member of ISO and one of the world’s largest providers of ISO training courses, recognized by certification bodies globally.

📋 Get ISO 13485 certified → ISOQAR ISO 13485 Certification — ISOQAR is a UKAS-accredited certification body — one of the most recognized in the industry for ISO management system certification.

What Is ISO 13485?

Medical device quality management infographic showing ISO 13485 certification concept with medical equipment and headline “What Is ISO 13485? Complete Guide (2026)”. — ISO 13485 defines the quality management system requirements for medical device manufacturers, focusing on regulatory compliance, risk management, and consistent product quality.

ISO 13485:2016 is the international standard for quality management systems specific to the medical device industry. It specifies requirements for a QMS that enables an organization to consistently design, develop, produce, and deliver safe and effective medical devices and related services.

ISO 13485 is used as the baseline QMS framework by regulatory authorities and certification bodies in most major medical device markets — including Health Canada, the EU MDR, MDSAP, and since February 2, 2026, the FDA’s QMSR under 21 CFR Part 820.

ISO 13485 covers the full scope of quality management system requirements:

Context of the organization and QMS scope
Management responsibility, quality policy, and management review
Resource management — personnel, infrastructure, and work environment
Product realization — design and development, purchasing, production, and service provision
Measurement, analysis, and improvement — internal audits, complaint handling, CAPA, and corrective action

What ISO 13485 requires on risk: ISO 13485 requires risk-based thinking throughout the quality management system. Risk management must be planned as part of product realization (Clause 7.1), integrated into design and development (Clause 7.3), applied to supplier controls (Clause 7.4), and fed by post-market surveillance feedback (Clause 8.2). The standard references ISO 14971 explicitly in its Clause 7.1 note and implicitly throughout its design and development requirements.

What ISO 13485 does not do is specify the methodology for risk management. It does not define how to identify hazards, estimate risks, evaluate acceptability, or control residual risk. That is what ISO 14971 does.

For a complete overview of ISO 13485 requirements, see What Is ISO 13485? Complete Guide.

What Is ISO 14971?

ISO 14971:2019 is the international standard for the application of risk management to medical devices. It provides the structured methodology — terminology, principles, and process — for identifying hazards, estimating and evaluating risks, implementing risk controls, and monitoring risk throughout the entire device lifecycle.

ISO 14971 covers:

Risk management planning — scope, lifecycle phases, risk acceptability criteria
Hazard identification — under both normal use and fault conditions
Risk estimation — probability of harm and severity of harm
Risk evaluation — comparison against acceptability criteria
Risk control — priority order: design, protective measures, information for safety
Evaluation of overall residual risk — including benefit-risk analysis where required
Risk management review — pre-release review with identified reviewers
Production and post-production information — systematic feedback into the risk management file

What ISO 14971 adds beyond ISO 13485: While ISO 13485 says risk management is required throughout the QMS, ISO 14971 specifies exactly how that risk management must be structured, documented, and maintained. The Risk Management File (RMF) — the central documentation output of the ISO 14971 process — is the evidence base that demonstrates a manufacturer has systematically identified hazards, evaluated risks, implemented controls, and monitored effectiveness.

For a complete overview of ISO 14971 requirements, see What Is ISO 14971? Risk Management for Medical Devices Explained.

ISO 14971 vs ISO 13485 — Key Differences

Element	ISO 13485:2016	ISO 14971:2019
Standard type	Quality management system standard	Risk management standard
Purpose	Define QMS requirements for medical device manufacturers	Define the risk management process for medical devices
Scope	Entire quality management system	Risk management specifically
Risk coverage	Requires risk-based thinking throughout QMS	Specifies how risk management must be conducted
Key output	Certified, compliant QMS	Risk Management File (RMF)
Certification	Certifiable — third-party certification available	Not certifiable on its own
Published by	ISO Technical Committee 210 (ISO/TC 210)	ISO Technical Committee 210 (ISO/TC 210)
Current edition	ISO 13485:2016	ISO 14971:2019
Applies to	Manufacturers, suppliers, contract manufacturers	All organizations involved in device lifecycle
Risk methodology	Not specified	Six-step structured process
Hazard analysis	Referenced but not detailed	Defined in detail
Risk Management File	Not specified	Required
Benefit-risk analysis	Not addressed	Required when overall residual risk is unacceptable
Post-production monitoring	Addressed through complaint handling and feedback	Explicitly required as ongoing RMF input
QMSR status	Incorporated by reference into 21 CFR Part 820	Expected framework; referenced through ISO 13485

Best for:

ISO 13485: Any organization that designs, manufactures, or supplies medical devices and needs a certified quality management system
ISO 14971: The same organizations — it provides the risk management methodology that ISO 13485’s requirements assume is in place

Where ISO 13485 References ISO 14971

Infographic mapping ISO 13485 clauses to corresponding ISO 14971 risk management requirements, showing how quality management processes trigger risk management activities across the medical device lifecycle. — ISO 13485 establishes quality system requirements, while ISO 14971 provides the risk management framework that connects planning, design, purchasing, feedback, and improvement activities throughout the medical device lifecycle.

ISO 13485 references ISO 14971 at specific points throughout its clause structure. Understanding exactly where these references occur is critical for building a compliant integrated system.

Clause 7.1 — Planning of Product Realization

Clause 7.1 requires that risk management activities be planned as part of product realization. The note to this clause states: “Further information can be found in ISO 14971.” This is the most direct reference to ISO 14971 in the standard.

Clause 7.3 — Design and Development

The design and development requirements of ISO 13485 are where ISO 14971 integration is most intensive. Design inputs must include risk management outputs. Design verification and validation activities must address risks. The Design and Development File (DDF) must reference risk management records.

Clause 7.4 — Purchasing

ISO 13485 Clause 7.4 requires that purchasing controls be proportionate to the risk the external provider poses to the finished device. The extent of supplier qualification, incoming inspection, and monitoring is determined by risk — which requires a risk framework to apply.

Clause 8.2 — Monitoring and Measurement

Post-market surveillance and complaint handling data collected under Clause 8.2 must feed back into the risk management process. ISO 14971 Clause 11 (Production and Post-Production Information) specifies how this information must be systematically reviewed and how it triggers updates to the Risk Management File.

Clause 8.5 — Improvement

CAPA activities under Clause 8.5 must consider risk. Significant quality failures identified through corrective action must evaluate whether the risk management file needs to be updated — connecting the two standards at the improvement level of the QMS.

At this point, most organizations beginning ISO 13485 implementation should:

📋 Purchase both ISO 13485:2016 and ISO 14971:2019 together as a bundle — the clause-by-clause integration means implementing one without the other creates immediate documentation gaps that auditors will identify.

→ ISO Standards Bundle — ANSI Webstore — Save up to 50% purchasing both standards together

Is ISO 14971 Actually Mandatory Under ISO 13485?

This is one of the most debated questions in the medical device quality community, and the honest answer is more nuanced than most articles present.

The technical answer: ISO 14971 is not formally mandated by ISO 13485. The reference in Clause 7.1 is a note — informative guidance, not a normative requirement. A manufacturer could theoretically implement a risk management process using a different methodology and still demonstrate conformance to ISO 13485’s risk-based requirements.

The practical answer: In the real world, ISO 14971 is effectively mandatory for any organization pursuing ISO 13485 certification or operating in regulated markets. Here’s why:

Certification bodies expect it. When a UKAS-accredited certification body audits your ISO 13485 QMS, the auditors evaluating your risk management program will be assessing it against the ISO 14971 framework — because that is the internationally recognized methodology for medical device risk management. A risk management program that doesn’t follow ISO 14971’s structure will face significant findings regardless of the technical argument about normative versus informative references.

Regulatory bodies reference it. The EU MDR, Health Canada, TGA, and MDSAP all reference ISO 14971 as the expected risk management framework. Operating without it creates regulatory exposure in every major market.

FDA QMSR changes the equation significantly — which brings us to the most important development of 2026.

The QMSR Changes the Practical Answer

The FDA’s Quality Management System Regulation (QMSR), effective February 2, 2026, incorporated ISO 13485:2016 by reference into 21 CFR Part 820. Since ISO 13485 explicitly references ISO 14971, that reference now carries federal regulatory weight.

Under the FDA’s new inspection program — Compliance Program 7382.850 — FDA investigators are expected to start inspections by reviewing the risk management file and following risk documentation into other quality system areas. The risk management file is the inspection roadmap. If your risk management program is not structured against ISO 14971, your risk management file will not hold up under that inspection approach.

Additionally, the QMSR extended risk management expectations beyond design controls — where the old QSR concentrated them — to the entire quality system. This is precisely what ISO 14971 requires: risk management planning, hazard identification, risk control, and post-production monitoring integrated across the device lifecycle, not just in the design phase.

The bottom line under QMSR: Whether or not ISO 14971 is technically mandatory in the normative sense of ISO 13485, it is the framework FDA investigators will use to evaluate your risk management program. Operating without it under the current inspection regime is an inspection liability.

⚠️ QMSR effective February 2, 2026: If your risk management program is not built on the ISO 14971 framework, this is your highest-priority gap for QMSR compliance.

For the complete QMSR transition guide, see FDA QSR vs ISO 13485 — The Complete QMSR Transition Guide.

How the Two Standards Work Together in Practice

The integration of ISO 13485 and ISO 14971 is not a separate parallel process — it is woven into how the QMS functions. Here is how the two standards interact at each stage of the device lifecycle:

Concept and Planning Stage

ISO 13485 Clause 7.1 requires risk management to be planned as part of product realization. ISO 14971 provides the Risk Management Plan — the document that defines scope, lifecycle phases, risk acceptability criteria, and the methods that will be used throughout the device’s life.

Design and Development

ISO 13485 Clause 7.3 requires design inputs to include risk management outputs and design outputs to be reviewed against inputs. ISO 14971 provides hazard identification and risk analysis — the outputs of which flow directly into design input requirements, design verification criteria, and design validation protocols.

Purchasing and Supplier Controls

ISO 13485 Clause 7.4 requires supplier controls proportionate to supplier risk. ISO 14971’s risk framework defines what “risk” means in this context — the severity and probability of harm that could result from supplier failures. Risk level drives supplier classification, incoming inspection intensity, and qualification requirements.

Production

ISO 13485 Clause 7.5 requires controlled production conditions and validation of special processes. Risk management under ISO 14971 determines which processes require validation (those where outputs cannot be fully verified) and what monitoring is required during production.

Post-Market Surveillance and CAPA

ISO 13485 Clause 8.2 requires systematic collection of post-market information. ISO 14971 Clause 11 requires that production and post-production information be systematically reviewed and fed back into the risk management file. When complaint data or CAPA findings reveal new hazards or indicate that risk estimates were incorrect, the Risk Management File must be updated.

This is where the most common gap exists in practice: organizations that treat risk management as a design-phase deliverable and do not maintain the connection between post-market data and the risk management file. Under QMSR, this gap is visible to FDA investigators within the first day of an inspection.

📋 Free Download: ISO 13485 Gap Assessment Checklist Section 6 covers ISO 14971 risk management integration specifically — risk management plan requirements, RMF structure and completeness, post-production feedback, and QMSR inspection implications. Download Free Checklist

The Risk Management File — Where They Intersect Most Clearly

Infographic comparing ISO 9001 risk-based thinking with ISO 13485 and ISO 14971 medical device risk management requirements using an integrated Venn diagram layout. — Both standards require risk management — but the depth and formality differ significantly. ISO 9001 uses general risk-based thinking, while ISO 13485 requires formal medical device risk management aligned with ISO 14971 throughout the product lifecycle.

The Risk Management File (RMF) is the single most important integration point between ISO 13485 and ISO 14971. It is the documentation output of the ISO 14971 process, and it is the record that connects risk management to every other element of the ISO 13485 QMS.

The RMF is not a single document. It is an organized collection of records that includes:

Risk Management Plan — scope, lifecycle phases, acceptability criteria, methodology
Risk analysis records — hazard identification, risk estimation
Risk evaluation records — comparison against acceptability criteria
Risk control records — selected measures, implementation records, verification
Overall residual risk evaluation — benefit-risk analysis where required
Risk Management Review — pre-release review with identified reviewers
Post-production information records — systematic review of real-world performance data

Under ISO 13485, the DDF (Design and Development File) must contain or reference risk management records. Under the QMSR and CP 7382.850, the RMF is where FDA investigators begin their inspection — tracing risk documentation into design controls, CAPA, complaint handling, and post-market surveillance.

A Risk Management File that was completed at device release and has not been updated since is one of the most common and most significant findings under the current inspection approach. The RMF is a living document. It must be updated throughout the device’s commercial life as post-production information is gathered and evaluated.

If your organization is already ISO 13485 certified and is assessing QMSR readiness, the current state of your Risk Management File is the single most important thing to evaluate first.

At this point, most organizations preparing for QMSR inspection should:

📋 Conduct a formal review of whether your Risk Management File has been updated since device release — and whether post-market complaint and CAPA data is systematically feeding into it. This is the highest-frequency inspection gap under CP 7382.850.

From the Shop Floor

After 25 years in heavy industrial manufacturing and quality systems, the most consistent pattern I see when organizations implement both ISO 13485 and ISO 14971 is this: they implement risk management well during design and development, and then they stop.

The Risk Management File is completed before device release. The risk management review is signed off. The certification audit passes. And then for the next three years, every complaint, every CAPA, every production nonconformance is handled in its own system — with no connection back to the risk management file that is supposed to be the living record of everything known about how the device can cause harm.

Three years later, an FDA investigator arrives under CP 7382.850 with the risk management file as their starting point. They trace a complaint about device malfunction into the CAPA system. They find a corrective action that was opened and closed. They look for the connection back to the risk management file — the evaluation of whether this complaint revealed a new hazard or indicated that an existing risk estimate was incorrect. The connection doesn’t exist.

That is not an ISO 13485 finding. It is not an ISO 14971 finding. It is a QMSR finding, because under the QMSR that connection is an expected element of a functioning integrated quality and risk management system.

The organizations that handle this well are the ones that treat the RMF update as a standing agenda item in management review — not a corrective action triggered by an audit finding. Post-market data goes into the RMF review process because the system requires it, not because an investigator asked for it.

That is what the integration of ISO 13485 and ISO 14971 is supposed to produce. It is also what separates manufacturers who pass inspections from those who merely survive them.

Which Standard Do You Buy First?

Both ISO 13485 and ISO 14971 are required for any serious medical device quality management implementation. The practical question is which to acquire and read first.

Buy ISO 13485 first if your organization is beginning the certification journey. ISO 13485 defines the overall QMS framework — understanding its requirements first gives you the context for understanding where and why ISO 14971 integrates.

Buy ISO 14971 immediately after — or together as a bundle. You cannot build a compliant risk management program from summaries or paraphrases. Both standards must be purchased, controlled as external documents within your QMS (as required under QMSR), and read by the people building your system.

For a complete overview of available medical device standards, see the Standards Library — Medical Devices Section.

The bundle option saves significantly. The ANSI Webstore offers the ISO 13485 and ISO/TR 14969 Quality Management Systems Medical Devices Package which includes both documents together at a meaningful discount versus individual purchases.

📋 ISO 13485:2016 — ANSI Webstore — use coupon CC2026 for 5% off

📋 ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off

📋 ISO Standards Bundle — Save up to 50%

Frequently Asked Questions

What is the main difference between ISO 14971 and ISO 13485?

ISO 13485 is a quality management system standard that defines what a medical device manufacturer’s QMS must cover — including the requirement that risk management be applied throughout the system. ISO 14971 is a risk management standard that defines how risk management must be conducted — the six-step process, the required documentation, and the Risk Management File structure. ISO 13485 requires risk management. ISO 14971 specifies how to do it.

Is ISO 14971 required if you have ISO 13485?

ISO 14971 is not formally mandated by ISO 13485’s normative requirements — the reference in Clause 7.1 is a note, not a normative requirement. However, certification bodies evaluate risk management programs against the ISO 14971 framework, and under the FDA’s QMSR (effective February 2, 2026), risk management expectations now carry federal regulatory weight. For practical purposes, ISO 14971 is effectively required for any organization pursuing ISO 13485 certification or operating in regulated markets.

Can you be certified to ISO 14971?

No. ISO 14971 is not a certifiable standard — there is no third-party certification to ISO 14971 itself. ISO 13485 is the certifiable standard. However, ISO 13485 certification implicitly requires that risk management is conducted in a way consistent with ISO 14971, since that is the framework certification bodies evaluate against.

Which came first — ISO 13485 or ISO 14971?

Both standards have long histories. ISO 14971 was first published in 2000, with major revisions in 2007 and 2019. ISO 13485 was first published in 1996, revised in 2003, and again in 2016. The 2016 edition of ISO 13485 was developed with the intent of aligning more closely with the 2012 draft of ISO 14971, ensuring stronger integration between the two standards.

Does ISO 14971 apply to software as a medical device?

Yes. ISO 14971:2019 explicitly applies to Software as a Medical Device (SaMD). The companion document ISO/TR 24971 provides specific guidance on applying ISO 14971 to software, including cybersecurity risk considerations.

How does the QMSR affect the relationship between ISO 13485 and ISO 14971?

The QMSR (effective February 2, 2026) incorporated ISO 13485 by reference into 21 CFR Part 820. Since ISO 13485 references ISO 14971, that reference now carries federal regulatory weight. FDA investigators under the new Compliance Program 7382.850 start inspections with the risk management file — which is the primary output of the ISO 14971 process. The QMSR also extended risk management expectations across the entire QMS rather than concentrating them in design controls as the old QSR did.

What is the Risk Management File and which standard requires it?

The Risk Management File (RMF) is the organized collection of records that documents all risk management activities for a specific medical device — risk management plan, hazard analysis records, risk evaluation records, risk control records, overall residual risk evaluation, risk management review, and post-production information records. It is required by ISO 14971, not ISO 13485 directly. However, under ISO 13485, the Design and Development File must contain or reference risk management records — and under the QMSR, the RMF is what FDA investigators use as their inspection roadmap.

Do I need ISO/TR 24971 as well?

ISO/TR 24971:2020 is the technical report companion to ISO 14971:2019. It provides practical guidance on implementing ISO 14971’s requirements — methods for hazard identification, risk estimation, benefit-risk analysis, and software risk management. Unlike ISO 14971, it is guidance rather than a standard with requirements. For organizations building or rebuilding their risk management program, ISO/TR 24971 is a valuable implementation companion. It is not required, but it is practically useful.

How does ISO 14971 differ from ISO 31000?

ISO 14971 is specific to medical device risk management and defines risk in terms of patient harm — the combination of probability and severity of harm to people. ISO 31000 is a broader enterprise risk management standard with a wider definition of risk that includes any effect on objectives. The two are not interchangeable in the medical device context. ISO 14971 is the expected framework for medical device risk management. ISO 31000 is not.

✅ Free Resources

📋 ISO 13485 Gap Assessment Checklist — 64 items across 7 sections including ISO 14971 risk management integration requirements and all four FDA QMSR bridge requirements. Identify your gaps before your first audit.

📋 Manufacturing Compliance Checklist — ISO 9001, 14001, 45001 & OSHA — 50 items with gap scoring across all compliance systems.

📋 Supplier Quality Checklist — ISO 9001 Clause 8.4 — all supplier controls auditors evaluate, 45 items with scoring.

📋 ISO 9001 Implementation Roadmap — The exact 5-phase process from gap assessment to Stage 2 audit clearance.

Not Sure What to Do Next?

✅ You need the official ISO 13485:2016 standard 📋 ISO 13485:2016 — ANSI Webstore — use coupon CC2026 for 5% off

✅ You need the official ISO 14971:2019 standard 📋 ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off

✅ You want to save buying both standards together 📋 ISO Standards Bundle — ANSI Webstore — Save up to 50%

✅ You want to identify your ISO 13485 and QMSR compliance gaps before spending anything 📋 Download the Free ISO 13485 Gap Assessment Checklist

✅ You need ISO 13485 training before implementation 📋 ISO 13485 Training — BSI Group

✅ You are ready to pursue ISO 13485 certification 📋 ISOQAR ISO 13485 Certification

✅ You want to understand what ISO 13485 requires 📋 What Is ISO 13485? Complete Guide

✅ You want to understand what ISO 14971 requires 📋 What Is ISO 14971? Risk Management for Medical Devices

✅ You want to understand the FDA QMSR and its impact 📋 FDA QSR vs ISO 13485 — The Complete QMSR Transition Guide

✅ You want to compare ISO 9001 and ISO 13485 📋 ISO 9001 vs ISO 13485 — Key Differences

✅ You want to understand ISO 13485 purchase options and cost 📋 Buy ISO 13485 — Complete Guide 📋 How Much Does ISO 13485 Cost?

✅ You want to browse all available medical device standards 📋 Standards Library — Medical Devices & Regulated Manufacturing 📋 Popular Standards — Most Frequently Purchased

Still Figuring Out Where to Start?

If you’re not ready to purchase or certify yet — that’s normal. ISO 13485 and ISO 14971 implementation decisions typically take three to six months from first research to commitment.

The best next step for most organizations at this stage:

📋 Download the free ISO 13485 Gap Assessment Checklist — it covers all 64 clause requirements including the ISO 14971 integration section and the four QMSR bridge requirements. It takes 30 minutes and tells you exactly where your gaps are before you spend anything.

Download Free Checklist — No Cost

ISO 13485 and ISO 14971 Are Not Optional to Each Other

ISO 13485 tells you risk management is required across your quality management system. ISO 14971 tells you how to conduct it. One without the other produces either a QMS with undefined risk methodology or a risk management program without a quality system framework to integrate it.

Under the FDA’s QMSR, effective February 2, 2026, that integration is no longer just a best practice — it is what federal regulatory inspection expects. FDA investigators start with the risk management file. They follow it into design controls, CAPA, complaint handling, and post-market surveillance. A quality management system that treats risk management as a design-phase deliverable rather than a lifecycle discipline will not hold up under that inspection approach.

The organizations that get this right are the ones that treat the Risk Management File as a living operational document — not a certification artifact. They update it because post-market data flows into it systematically. They connect CAPA to it because the system requires the connection. They identify new hazards from real-world performance data because that is what ISO 14971 Clause 11 requires and what QMSR now enforces.

That is what implementing both standards properly actually produces.

At The Standards Navigator, complex standards are translated into practical, real-world guidance you can act on.

✅ Get updates on new standards, implementation strategies, and compliance insights ✅ Be first to access new guides, tools, and checklists

Subscribe below to stay ahead.

What Is ISO 14971? Risk Management for Medical Devices Explained (2026 Guide)

ISO 14971 is not optional supplementary guidance for ISO 13485 — it is the required risk management framework woven throughout the medical device lifecycle. This guide covers what ISO 14971:2019 requires clause by clause, how its six-step process works across the device lifecycle, what changed in the 2019 edition, and why the FDA’s QMSR makes a well-maintained Risk Management File more critical than ever.

ISO 14971 is not optional supplementary guidance for ISO 13485 — it is the required risk management framework woven throughout the medical device lifecycle. Here’s what it requires, how it works, and why the FDA’s QMSR makes understanding it more important than ever.

Affiliate Disclosure: Some links in this article are affiliate links. If you purchase through them, The Standards Navigator may earn a commission at no additional cost to you.

From the Shop Floor

Risk management in manufacturing is not a new concept. Every process engineer who has ever run a failure modes and effects analysis on a production line understands the core logic: identify what can go wrong, estimate how likely it is and how bad it would be, put controls in place, and verify those controls work.

What ISO 14971 adds to that foundation is structure, lifecycle scope, and documentation discipline.

After 25 years in heavy industrial manufacturing — including quality systems, process control, and operational risk — the single most consistent gap I see in medical device risk management is the treatment of the Risk Management File as a design-phase deliverable rather than a living operational document. Teams build an impressive RMF during product development, get through their certification audit, and then let the file sit static while the real world generates new information about how the device actually performs.

That approach worked well enough under the old QSR. It does not work under the QMSR.

FDA investigators under CP 7382.850 are not looking at your RMF to confirm it was done — they are using it as a roadmap to evaluate whether your entire quality system is functioning as an integrated risk management framework. A risk management file that hasn’t been updated since device release is not a minor documentation gap. It is evidence that your risk management process is not integrated with complaint handling, CAPA, and post-market surveillance the way the QMSR requires.

The organizations I have seen handle this well treat the RMF update as a standing agenda item in management review — not a corrective action triggered by an audit finding. If post-market data is generating complaints, those complaints are being evaluated in the context of the risk management file every quarter. That is the operating model QMSR expects.

ISO 14971 Is the Standard Your QMS Is Already Required to Implement

If you are pursuing ISO 13485 certification, operating under the FDA’s QMSR, or manufacturing medical devices for any major regulated market, ISO 14971 is not a standard you get to choose whether to implement.

ISO 13485:2016 explicitly requires risk management per ISO 14971 throughout the medical device lifecycle — in design controls, production processes, supplier controls, complaint handling, and post-market surveillance. Under the FDA’s Quality Management System Regulation (QMSR), effective February 2, 2026, that requirement now carries federal regulatory weight. FDA investigators under Compliance Program 7382.850 are expected to use the risk management file as their inspection roadmap.

Yet despite being one of the most referenced standards in medical device regulation, ISO 14971 remains one of the least understood. Most manufacturers know it exists. Far fewer understand what it actually requires, how its six-step process works across the device lifecycle, or why the 2019 edition introduced changes that many organizations still haven’t fully implemented.

This guide covers all of it — what ISO 14971 is, what it requires clause by clause, how it integrates with ISO 13485 and the QMSR, and what your risk management program needs to look like in practice.

In This Guide

What ISO 14971 is and why it exists
Who needs ISO 14971
The six-step ISO 14971 risk management process
Key clause-by-clause breakdown
What changed in the 2019 edition
The Risk Management File — what it contains and how it’s structured
ISO 14971 and ISO 13485 — how they integrate
ISO 14971 under the FDA QMSR
ISO/TR 24971 — the companion guidance document
How to buy the official standard
Frequently asked questions

✅ Start Here (Top Resources)

📋 Purchase the official ISO 14971:2019 standard → ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off through December 31, 2026

📋 Purchase the official ISO 13485:2016 standard — required companion → ISO 13485:2016 — ANSI Webstore — use coupon CC2026 for 5% off

📋 Save up to 50% buying both standards as a bundle → ISO Standards Packages — ANSI Webstore

📋 Get ISO 13485 training that covers ISO 14971 integration → BSI Group ISO 13485 Training

📋 Get ISO 13485 certified with an accredited certification body → ISOQAR ISO 13485 Certification

What Is ISO 14971?

ISO 14971 is the international standard for the application of risk management to medical devices. The current version — ISO 14971:2019 — is the third edition, published in December 2019. It specifies the terminology, principles, and a structured process for identifying hazards associated with medical devices, estimating and evaluating the associated risks, controlling those risks, and monitoring the effectiveness of controls throughout the entire device lifecycle.

The standard applies to:

Physical medical devices of all classifications
Software as a Medical Device (SaMD)
In vitro diagnostic (IVD) medical devices
Combination products where the device constituent part requires risk management

Before ISO 14971, there was no universally accepted methodology for risk management in the medical device industry. Different manufacturers used different approaches, different terminology, and different standards for what constituted acceptable risk. ISO 14971 introduced a standardized process that could be consistently applied across the industry globally — giving regulators, certification bodies, and trading partners a shared framework for evaluating whether a manufacturer’s risk management is adequate.

Risk, as defined by ISO 14971, is the combination of two components:

The probability that harm will occur
The severity of that harm

This definition is important because it shapes the entire risk management process. A high-severity potential harm that is extremely unlikely to occur produces a different risk level than a moderate-severity harm that occurs frequently. ISO 14971 requires manufacturers to evaluate both dimensions systematically — not rely on intuition or experience alone.

Who Needs ISO 14971?

ISO 14971 is effectively required for any organization involved in the medical device supply chain. Specifically:

Organizations that must implement ISO 14971:

Medical device manufacturers — it is explicitly required by ISO 13485 and referenced throughout FDA QMSR, EU MDR, Health Canada, TGA (Australia), and most other major regulatory frameworks
Design-responsible organizations developing medical devices or device software
Contract manufacturers producing devices under a design owner’s technical file

Organizations that should implement ISO 14971:

Component suppliers whose products are incorporated into medical devices — risk management requirements are increasingly flowed down through quality agreements
Software developers producing SaMD or software incorporated into medical devices
Sterilization service providers — sterilization process risk must be managed within the device’s overall risk management framework

A critical distinction: ISO 14971 is not legally mandated in the same way a regulation is — regulators like the FDA do not list it as a statutory requirement. However, regulators worldwide recognize ISO 14971 as the state of the art for medical device risk management. Non-conformance with ISO 14971 — or the absence of a risk management program built on its framework — creates significant regulatory exposure. For practical purposes, ISO 14971 is mandatory for any organization intending to demonstrate that their device is safe and effective.

The ISO 14971 Risk Management Process — Six Steps

Infographic illustrating the six-step ISO 14971 medical device risk management process: Risk Analysis, Risk Evaluation, Risk Control, Overall Residual Risk, Risk Management Review, and Post-Production Information. — The six-step ISO 14971 risk management process creates a structured lifecycle approach for identifying hazards, controlling risks, evaluating residual risk, and continuously improving medical device safety.

ISO 14971 defines a six-step risk management process that applies across the entire device lifecycle — from initial concept through design, production, and post-market activities.

Step 1 — Risk Analysis

Risk analysis is the systematic use of available information to identify hazards and estimate the risks associated with a medical device. It consists of two activities:

Hazard identification: Identifying all reasonably foreseeable hazards associated with the device under both normal use conditions and fault conditions. The 2019 edition specifically requires both normal and fault conditions to be considered — a change from the 2007 edition which emphasized fault conditions primarily.

Sources of hazards include:

Device energy sources (electrical, thermal, mechanical, radiation)
Device materials and their biological interactions
Use environment and user characteristics
Reasonably foreseeable misuse
Software failures and cybersecurity vulnerabilities
Interactions with other devices

Risk estimation: For each hazardous situation identified, estimating the risk by determining the probability of occurrence of harm and the severity of that harm. ISO 14971 does not specify acceptable risk levels — manufacturers must establish their own objective criteria based on regulatory requirements, industry standards, and clinical context.

Step 2 — Risk Evaluation

Risk evaluation is the process of comparing estimated risks against the manufacturer’s defined risk acceptability criteria to determine whether risk reduction is required. If the estimated risk exceeds acceptable levels, the process moves to risk control. If the risk is within acceptable limits, it is documented as acceptable residual risk and monitored.

Step 3 — Risk Control

Risk control is the process of implementing and verifying measures to reduce risks that exceed acceptable levels. ISO 14971 requires risk control measures to be implemented in a defined priority order:

Inherent safety by design — eliminate or reduce hazards through design decisions (preferred)
Protective measures — guards, alarms, interlocks in the device or manufacturing process
Information for safety — warnings, instructions for use, training requirements (last resort)

After implementing risk control measures, the residual risk — the risk remaining after controls — must be estimated and evaluated again. The process is iterative: if residual risk is still unacceptable, additional risk control measures must be implemented.

Risk control measures must also be evaluated for introduced risks — a control measure that eliminates one hazard may introduce a new one.

Step 4 — Evaluation of Overall Residual Risk

After all individual risks have been addressed, the overall residual risk of the device must be evaluated — not just each individual risk in isolation. If the overall residual risk is not acceptable using the manufacturer’s risk acceptability criteria, a benefit-risk analysis must be performed.

Benefit-risk analysis (introduced as a formal requirement in the 2019 edition) evaluates whether the clinical benefits of the device outweigh the overall residual risk in the context of the device’s intended use. If the benefits outweigh the risks, and appropriate information is provided to users, the device may be released. If the benefits do not outweigh the risks, the device cannot be released — additional risk control measures are required.

Step 5 — Risk Management Review

Before a device is released for distribution, a formal risk management review must be completed. The 2019 edition changed the title of this clause from “Risk Management Report” to “Risk Management Review” — a deliberate signal that this is an active review activity, not simply a summary document.

The review must confirm:

The risk management plan has been fully implemented
The overall residual risk is acceptable
Appropriate methods are in place to collect and review production and post-production information

Reviewers must be identified in the risk management plan in advance — they cannot be appointed after the fact.

Step 6 — Production and Post-Production Information

Risk management does not end when the device is released. ISO 14971 requires a systematic process for collecting and reviewing information from production and post-market activities throughout the device’s commercial life. This includes:

Complaint data and adverse event reports
Post-market surveillance information
Production nonconformances and CAPA trends
New scientific and technical information relevant to device safety

When this information indicates that the risk management process needs to be updated — that a new hazard has been identified, or that an existing risk estimate was incorrect — the risk management file must be revised and risk control measures re-evaluated.

ISO 14971 Clause-by-Clause Breakdown

Clause	Title	Key Content
1	Scope	Applicability to all medical devices, SaMD, IVDs, combination products
2	Normative references	ISO 9000:2015 for defined terms
3	Terms and definitions	31 defined terms including risk, hazard, harm, hazardous situation, benefit
4	General requirements	Risk management system requirements, management responsibilities, competence requirements
5	Risk management planning	Risk management plan requirements — device scope, lifecycle phases, risk acceptability criteria
6	Risk analysis	Intended use, hazard identification, risk estimation
7	Risk evaluation	Comparison to acceptability criteria, benefit-risk analysis (Clause 7.4)
8	Risk control	Control option analysis, measure implementation, residual risk evaluation, introduced risks
9	Evaluation of overall residual risk	Overall residual risk acceptability, benefit-risk if needed
10	Risk management review	Pre-release review requirements, reviewer identification
11	Production and post-production activities	Information collection, new hazard identification, risk file updates

What Changed in ISO 14971:2019

The 2019 edition is the third edition of ISO 14971, replacing the 2007 version. Several changes have practical implementation implications:

Benefit-risk analysis is now a formal requirement. The 2019 edition formally introduced benefit-risk analysis as a defined process step (Clause 7.4) when overall residual risk is not acceptable under the manufacturer’s criteria alone. The 2007 edition referenced this concept but did not treat it as a structured requirement. The FDA’s influence here is direct — the FDA revised its language to place “benefit” before “risk” for novel device submissions, and the ISO 14971 committee adopted this framing in the 2019 revision.

Both normal and fault conditions must be analyzed. Clause 5.4 of the 2019 edition explicitly requires identification of anticipated hazards under both normal use and fault conditions. The 2007 edition emphasized fault conditions — the 2019 edition closes that gap. This has direct implications for FMEA and hazard analysis documentation.

Post-production requirements are more prescriptive. The requirements for production and post-production information collection (Clause 11) are more detailed in the 2019 edition, with stronger emphasis on systematic feedback of real-world performance data into the risk management file.

Risk Management Review replaces Risk Management Report. The title change in Clause 9 (from “report” to “review”) reflects a substantive intent: the activity must be an active review with identified reviewers, not a passive summary document compiled at device release.

EN ISO 14971:2019 + A11:2021 for EU MDR. The European version of the standard includes Amendment A11:2021, which maps ISO 14971 requirements to the General Safety and Performance Requirements (GSPR) of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). Organizations selling into the EU need the A11 annex — organizations selling only in the U.S. do not, but the normative requirements are identical in both versions.

The Risk Management File

The Risk Management File (RMF) is the central documentation output of the ISO 14971 process. It is the organized collection of records that demonstrates a manufacturer has systematically identified hazards, evaluated risks, implemented controls, and monitored the effectiveness of those controls throughout the device lifecycle.

The RMF is not a single document. It is a defined collection of records that includes:

Risk Management Plan (RMP): Defines the scope of risk management activities, the lifecycle phases covered, the risk acceptability criteria, the risk estimation methodology, and the verification activities planned
Risk Analysis records: Hazard identification outputs, risk estimation records, FMEA or other analysis tool outputs
Risk Evaluation records: Comparison of estimated risks against acceptability criteria
Risk Control records: Selected control measures, implementation records, verification that controls achieved their intended risk reduction, evaluation of introduced risks
Overall Residual Risk evaluation: Documentation of the overall residual risk assessment and benefit-risk analysis if required
Risk Management Review: Pre-release review record with identified reviewers
Post-Production information records: Systematic records of production and post-market information reviewed against the risk management file

A common audit finding is a Risk Management File that functions as a static document compiled at device release — rather than a living record updated throughout the device’s commercial life as post-production information is gathered. Under the QMSR, FDA investigators start inspections with the risk management file. A static RMF that hasn’t been updated since initial device release is a significant inspection vulnerability.

Feature image promoting an ISO 13485 Gap Assessment Checklist for medical device manufacturers, contract manufacturers, and component suppliers preparing for certification and FDA QMSR compliance. — ISO 13485 Gap Assessment Checklist designed to help medical device manufacturers identify compliance gaps, prioritize actions, and prepare for certification and FDA QMSR requirements.

📋 How does your risk management program measure up? Section 6 of the free ISO 13485 Gap Assessment Checklist covers ISO 14971 integration specifically — risk management plan requirements, RMF structure, post-production feedback, and the QMSR inspection implications. Download Free Checklist

ISO 14971 and ISO 13485 — How They Integrate

ISO 14971 and ISO 13485 are companion standards — not alternatives. ISO 13485 is the quality management system framework. ISO 14971 is the risk management framework that ISO 13485 requires to be implemented throughout that QMS.

ISO 13485 references ISO 14971 in multiple clauses:

Clause 7.1 — Planning of product realization: Risk management activities must be planned as part of product realization
Clause 7.3 — Design and development: Risk management must be integrated throughout design and development activities
Clause 7.4 — Purchasing: Supplier controls must reflect risk — suppliers of higher-risk components require more rigorous qualification
Clause 8.2.1 — Feedback: Post-market feedback must be evaluated in the context of risk management
Clause 8.5 — Improvement: CAPA and continual improvement activities must consider risk management outputs

ISO 14971 is not optional supplementary guidance for ISO 13485. Organizations implementing ISO 13485 must purchase and implement ISO 14971. It is an external document that must be controlled under ISO 13485 Clause 4.2.4 — registered, version-controlled, and accessible to relevant personnel.

For a complete comparison of how ISO 13485 and risk management requirements interact, see ISO 9001 vs ISO 13485 — Key Differences.

📋 Buy ISO 13485:2016 — ANSI Webstore — use coupon CC2026 for 5% off

ISO 14971 Under the FDA QMSR

The FDA’s Quality Management System Regulation (QMSR), effective February 2, 2026, incorporated ISO 13485:2016 by reference into 21 CFR Part 820 — and with it, ISO 13485’s explicit requirement for risk management per ISO 14971.

Under QMSR, several specific changes elevate the practical importance of ISO 14971:

Risk management now extends across the entire QMS. Under the old QSR, risk management was concentrated primarily in design controls. Under QMSR, risk-based thinking is required throughout the entire quality system — supplier controls, production processes, CAPA, complaint handling, and post-market surveillance. ISO 14971 is the expected framework for implementing this expanded risk management scope.

FDA investigators start inspections with the risk management file. Under Compliance Program 7382.850 — the new inspection program that replaced QSIT on February 2, 2026 — FDA investigators are expected to begin inspections by reviewing the risk management file and following risk documentation into other quality system areas. A well-maintained, current risk management file is inspection preparation. An incomplete or static risk management file is an inspection liability.

Post-market surveillance feeds the risk management file. The QMSR’s requirements for production and post-production information — complaint handling, MDR, field corrections — are expected to feed systematically into the risk management file. Organizations that maintain complaint handling and risk management as separate, unconnected systems have a QMSR gap.

For the complete QMSR transition guide, see FDA QSR vs ISO 13485: The Complete QMSR Transition Guide.

ISO/TR 24971 — The Companion Guidance Document

ISO/TR 24971:2020 is the technical report published as a companion to ISO 14971:2019. Unlike ISO 14971, which is a normative standard (its requirements are mandatory for certification purposes), ISO/TR 24971 is guidance — it does not add requirements but provides practical methodology for implementing ISO 14971’s requirements.

ISO/TR 24971:2020 covers:

Guidance on risk management planning
Practical methods for hazard identification and risk estimation
Guidance on benefit-risk analysis
Application of risk management to software
Application of risk management to usability and human factors
Guidance on production and post-production information processes

For organizations building or rebuilding their risk management program, ISO/TR 24971 is the practical implementation companion to ISO 14971’s requirements. Many experienced quality and regulatory professionals recommend reading both together.

📋 ISO/TR 24971:2020 — ANSI Webstore — use coupon CC2026 for 5% off

How to Buy ISO 14971

ISO 14971 is a copyrighted document and must be purchased from an authorized source. It cannot be legally downloaded for free.

ANSI Webstore — Recommended U.S. Source

The ANSI Webstore is the authorized U.S. distributor for ISO standards. ISO 14971:2019 is available in PDF format with immediate download after purchase.

📋 ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off through December 31, 2026

Bundle with ISO 13485 — Save Up to 50%

Organizations implementing ISO 13485 need both standards. Purchasing as a bundle through the ANSI Webstore saves significantly compared to individual purchases.

📋 ISO Standards Bundles — Save up to 50%

For the complete guide to purchasing ISO 13485, see Buy ISO 13485 — Complete Purchasing Guide.

Frequently Asked Questions

What is ISO 14971 used for?

ISO 14971 is the international standard for applying risk management to medical devices. It provides the structured process — hazard identification, risk estimation, risk evaluation, risk control, overall residual risk evaluation, and post-production monitoring — that manufacturers must use to demonstrate that their devices are safe for their intended use.

Is ISO 14971 required for ISO 13485 certification?

Yes. ISO 13485 explicitly requires risk management per ISO 14971 throughout the medical device quality management system. Organizations cannot achieve ISO 13485 certification without demonstrating that their risk management program is built on the ISO 14971 framework. ISO 14971 must be controlled as an external document within the ISO 13485 QMS.

Is ISO 14971 required by the FDA?

ISO 14971 is not listed as a statutory FDA requirement. However, the FDA recognizes ISO 14971 as the state of the art for medical device risk management. Under the QMSR, effective February 2, 2026, ISO 13485 is incorporated by reference into 21 CFR Part 820 — and ISO 13485 explicitly requires ISO 14971. FDA investigators under CP 7382.850 use the risk management file as their inspection starting point. For practical purposes, ISO 14971 is effectively mandatory for any FDA-regulated medical device manufacturer.

What is the difference between ISO 14971:2007 and ISO 14971:2019?

The 2019 edition introduced several substantive changes: benefit-risk analysis is now a formal requirement when overall residual risk is not acceptable; both normal use and fault conditions must be analyzed during hazard identification; post-production requirements are more prescriptive; and the Risk Management Report was renamed Risk Management Review to signal an active review activity rather than a passive document.

What is the Risk Management File?

The Risk Management File (RMF) is the organized collection of records that demonstrates a manufacturer has systematically implemented the ISO 14971 risk management process. It includes the Risk Management Plan, hazard analysis records, risk evaluation records, risk control records, overall residual risk evaluation, risk management review, and post-production information records. The RMF is a living document — it must be updated throughout the device’s commercial life as post-production information is gathered.

What is ISO/TR 24971?

ISO/TR 24971:2020 is the technical report companion to ISO 14971:2019. It provides practical guidance on implementing ISO 14971’s requirements — methods for hazard identification, risk estimation, benefit-risk analysis, software risk management, and post-production information processes. It does not add normative requirements but is an essential practical companion for organizations building or rebuilding their risk management programs.

What is the difference between ISO 14971 and ISO 31000?

ISO 14971 is specific to medical device risk management and defines risk purely in terms of harm to people — the combination of probability of harm and severity of that harm. ISO 31000 is a broader enterprise risk management standard with a wider definition of risk that includes any effect on objectives, including positive risks (opportunities). The two standards serve different purposes and are not interchangeable in the medical device context.

Does ISO 14971 apply to software as a medical device?

Yes. ISO 14971:2019 explicitly applies to Software as a Medical Device (SaMD). ISO/TR 24971 provides specific guidance on applying ISO 14971 to software. The companion standard IEC 62304 — Medical Device Software Lifecycle Processes — also references ISO 14971 risk management requirements throughout its software development lifecycle requirements.

📥 Free Resources

👉 ISO 9001 Roadmap — Step-by-Step Implementation Guide
👉 Manufacturing Compliance Checklist — verify all compliance areas before your certification audit
👉 Supplier Quality Checklist — material supplier and tooling supplier qualification requirements

Not Sure What to Do Next?

✅ You need the official ISO 14971:2019 standard 📋 ISO 14971:2019 — ANSI Webstore — use coupon CC2026 for 5% off through December 31, 2026

✅ You also need ISO 13485:2016 — the required companion QMS standard 📋 ISO 13485:2016 — ANSI Webstore — use coupon CC2026 for 5% off

✅ You need the ISO/TR 24971 implementation guidance companion 📋 ISO/TR 24971:2020 — ANSI Webstore — use coupon CC2026 for 5% off

✅ You want to save buying multiple standards together 📋 ISO Standards Bundles — Save up to 50% — ANSI Webstore

✅ You need ISO 13485 training that covers ISO 14971 integration 📋 BSI Group ISO 13485 Training

✅ You are ready to pursue ISO 13485 certification 📋 ISOQAR ISO 13485 Certification

✅ You want to understand what ISO 13485 requires 📋 What Is ISO 13485? — Complete Guide

✅ You want to understand the FDA QMSR and how ISO 14971 fits 📋 FDA QSR vs ISO 13485 — The Complete QMSR Transition Guide

✅ You want to compare ISO 9001 and ISO 13485 📋 ISO 9001 vs ISO 13485 — Key Differences

✅ You want to understand ISO 13485 purchase options and cost 📋 Buy ISO 13485 — Complete Purchasing Guide 📋 How Much Does ISO 13485 Cost?

Risk Management Is Not a Deliverable. It’s an Operating Model.

ISO 14971 is not a checkbox on a certification audit list. It is the framework that determines whether the medical devices your organization produces — or supplies components for — are demonstrably safe for their intended use.

Under the FDA’s QMSR, effective February 2, 2026, that framework now carries federal regulatory weight. Risk management under QMSR extends across the entire quality system, and FDA investigators under CP 7382.850 are using the risk management file as their inspection roadmap.

The organizations that navigate this environment successfully are the ones that treat risk management as an operating discipline — not a documentation exercise. The Risk Management File is updated because post-market data is being systematically reviewed, not because an audit is scheduled. CAPA is connected to the risk management file because the quality system is integrated, not because an investigator asked to see the connection.

That is what ISO 14971, properly implemented, actually produces.

At The Standards Navigator, complex standards are translated into practical, real-world guidance you can act on.

✅ Get updates on new standards, implementation strategies, and compliance insights ✅ Be first to access new guides, tools, and checklists

Subscribe below to stay ahead.

The Matrix Changed. If Your Biological Evaluation Plan Still Reads Like 2018, You Have a Gap

In This Guide

Table of Contents

👉 Start Here (Top Resources)

Why the Evaluation Matrix Was Restructured

Contact Duration Categories, Defined

Daily Contact vs. Intermittent Contact

Reusable Devices and Total Exposure Period

Mapping Contact Category to Biological Endpoints

FDA’s Partial Recognition — What’s Excluded

Common Categorization Mistakes

Quick Audit Checklist

FAQ

Does ISO 10993-1:2025 require me to retest devices already on the market?

Is ISO 10993-1:2018 still valid to use?

What’s the difference between “prolonged” and “long-term” contact?

Does the 2025 edition apply to devices regulated under the EU MDR?

Is genotoxicity testing now mandatory for every prolonged-contact device?

Do I need a new Biological Evaluation Plan for every device?

How does ISO 14971 relate to my biological evaluation?

Where do I buy the current edition of ISO 10993-1?

📥 Free Resources

Not Sure What to Do Next?

The Standard Changed. Your Categorization Logic Should Too.

Don’t Let a Reviewer Find the Gap First

Subscribe

The Standard Behind Your Biocompatibility Testing Just Changed — Is Your Documentation Still Defensible?

In This Guide

Table of Contents

👉 Start Here (Top Resources)

What Is Biocompatibility, and Why ISO 10993 Matters

The ISO 10993 Series at a Glance

What Changed in ISO 10993-1:2025

ISO 10993 FDA Recognition: What’s Excluded and Why

Do You Need to Retest Already-Cleared Devices?

Where Biocompatibility Fits Into Your ISO 13485 QMS

Quick Audit Checklist

FAQ

What is biocompatibility testing for medical devices?

What is ISO 10993-1, and do I need to comply with it?

What changed between ISO 10993-1:2018 and ISO 10993-1:2025?

Has the FDA recognized ISO 10993-1:2025?

Do I need to retest devices already cleared under the 2018 edition?

Which parts of the ISO 10993 series apply to my device?

Is ISO 10993 the same as ISO 13485?

Where do I purchase ISO 10993 standards?

📥 Free Resources

Not Sure What to Do Next?

Documentation Gaps Don’t Show Up Until Someone’s Looking For Them

Subscribe

Your Risk Management File Is the First Thing an Auditor Opens

In This Guide

Table of Contents

👉 Start Here: Top Resources for Medical Device Risk Management

What ISO 14971:2019 Requires

How ISO 13485 Clause 7.1 Connects

The Five-Stage Risk Management Process

Stage 1: Risk Management Plan

Stage 2: Risk Analysis

Stage 3: Risk Evaluation

Stage 4: Risk Control

Stage 5: Residual Risk and Benefit-Risk Analysis

Setting Acceptable Risk Criteria

Risk Control Options and Residual Risk

The Risk Management File

Post-Production Information and Surveillance

Common Audit Findings in Risk Management Reviews

Training for Your Risk Management Team

FAQ

What is the difference between ISO 14971 and ISO 13485 for risk management?

Is ISO 14971 mandatory?

What is a risk management file?

How often should a risk management file be updated?

What risk analysis methods does ISO 14971 require?

What is the difference between a hazard, a hazardous situation, and harm in ISO 14971?

How does ISO 14971 relate to CAPA in ISO 13485?

What changed in ISO 14971:2019 compared to the 2007 edition?

📥 Free Resources

Not Sure What to Do Next?

Stay Current on Medical Device Compliance